Kraig Biocraft Laboratories (KBLB) 10-Q 10 Nov 20 2020 Q3 Quarterly report Financial data

Document Entity Information

Document Entity Information - shares	9 Months Ended
	Sep. 30, 2020	Nov. 10, 2020
Entity Registrant Name	Kraig Biocraft Laboratories, Inc
Entity Central Index Key	0001413119
Document Type	10-Q
Document Period End Date	Sep. 30, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2020
Common Stock Class A [Member]
Entity Common Stock, Shares Outstanding		854,410,001
Common Stock Class B [Member]
Entity Common Stock, Shares Outstanding		0

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Current Assets
Cash	$ 43,062	$ 125,024
Prepaid expenses	12,979	31,745
Total Current Assets	56,041	156,769
Property and Equipment, net	96,044	117,321
Operating lease right-of-use asset, net	385,436	473,242
Security deposit	3,518	3,518
Total Assets	541,039	750,850
Current Liabilities
Accounts payable and accrued expenses	520,410	560,948
Note payable - related party	1,492,000	642,000
Royalty agreement payable - related party	65,292	65,292
Accounts payable and accrued expenses - related party	4,614,733	4,145,465
Operating lease liability, current	122,028	110,678
Loan payable	60,000	60,000
SBA Pacheck Protection Loan	90,100
Total Current Liabilities	6,964,563	5,584,383
Long Term Liabilities
Loan payable, net of current	140,244	185,244
Operating lease liability, net of current	276,314	369,281
Total Liabilities	7,381,121	6,138,908
Commitments and Contingencies
Stockholders' Deficit
Preferred stock, value
Common Stock Issuable, 1,122,311 and 1,122,311 shares, respectively	22,000	22,000
Additional paid-in capital	4,909,082	2,412,969
Deferred Compensation
Accumulated Deficit	(34,111,200)	(29,797,906)
Total Stockholders' Deficit	(6,840,082)	(5,388,058)
Total Liabilities and Stockholders' Deficit	541,039	750,850
Series A Preferred Stock [Member]
Stockholders' Deficit
Preferred stock, value	5,217,800	5,217,800
Common Stock Class A [Member]
Stockholders' Deficit
Common stock, value	17,122,236	16,757,079
Common Stock Class B [Member]
Stockholders' Deficit
Common stock, value

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Preferred stock, no par value
Preferred stock, shares authorized	Unlimited	Unlimited
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock issuable	1,122,311	1,122,311
Series A Preferred Stock [Member]
Preferred stock, no par value
Preferred stock, shares issued	2	2
Preferred stock, shares outstanding	2	2
Common Stock Class A [Member]
Common stock, no par value
Common stock, shares authorized	Unlimited	Unlimited
Common stock, shares issued	854,410,001	844,468,378
Common stock, shares outstanding	854,410,001	844,468,378
Common Stock Class B [Member]
Common stock, no par value
Common stock, shares authorized	Unlimited	Unlimited
Common stock, shares issued
Common stock, shares outstanding

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Income Statement [Abstract]
Revenue
Operating Expenses
General and Administrative	366,243	826,571	3,507,302	1,066,724
Professional Fees	39,169	54,230	89,643	242,458
Officer's Salary	161,861	129,577	361,276	395,782
Rent - Related Party	3,556	2,487	9,819	11,913
Research and Development	27,626	43,987	65,408	87,228
Total Operating Expenses	598,455	1,056,852	4,033,448	1,804,105
Loss from Operations	(598,455)	(1,056,852)	(4,033,448)	(1,804,105)
Other Income/(Expenses)
Interest expense	(94,703)	(73,276)	(279,846)	(210,891)
Interest income		1,640		6,265
Total Other Income/(Expenses)	(94,703)	(71,636)	(279,846)	(204,626)
Net (Loss) before Provision for Income Taxes	(693,158)	(1,128,488)	(4,313,294)	(2,008,731)
Provision for Income Taxes
Net (Loss)	$ (693,158)	$ (1,128,488)	$ (4,313,294)	$ (2,008,731)
Net Income (Loss) Per Share - Basic and Diluted	$ 0	$ 0	$ (0.01)	$ 0
Weighted average number of shares outstanding during the period - Basic and Diluted	851,168,167	839,837,716	846,717,942	832,594,572

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Changes in Stockholders Deficit (Unaudited) - USD ($)	Preferred Stock - Series A [Member]	Common Stock - Class A [Member]	Common Stock - Class B [Member]	Common Stock - Class A Shares To be Issued [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Total
Beginning Balance at Dec. 31, 2018	$ 5,217,800	$ 15,145,798		$ 22,000	$ 2,043,235	$ (26,888,056)	$ (4,459,223)
Beginning Balance, shares at Dec. 31, 2018	2	816,883,910		1,122,311
Units issued for cash		$ 1,000,000					1,000,000
Units issued for cash, shares		14,797,278
Shares issued in exchange for accounts payable		$ 281,659					281,659
Shares issued in exchange for accounts payable, shares		4,052,652
Options issued for services - related parties					584,776		584,776
Exercise of warrants in exchange for stock		$ 329,622			(329,622)
Exercise of warrants in exchange for stock, shares		8,734,538
Cancellation of warrants issued for services					(19,915)		(19,915)
Imputed interest - related party					16,027		16,027
Net loss						(2,008,731)	(2,008,731)
Ending Balance at Sep. 30, 2019	$ 5,217,800	$ 16,757,079		$ 22,000	2,294,501	(28,896,787)	(4,605,407)
Ending Balance, shares at Sep. 30, 2019	2	844,468,378		1,122,311
Beginning Balance at Jun. 30, 2019	$ 5,217,800	$ 16,427,457		$ 22,000	2,033,777	(27,768,299)	(4,067,265)
Beginning Balance, shares at Jun. 30, 2019	2	835,733,840		1,122,311
Options issued for services - related parties					584,776		584,776
Exercise of warrants in exchange for stock		$ 329,622			(329,622)
Exercise of warrants in exchange for stock, shares		8,734,538
Imputed interest - related party					5,570		5,570
Net loss						(1,128,488)	(1,128,488)
Ending Balance at Sep. 30, 2019	$ 5,217,800	$ 16,757,079		$ 22,000	2,294,501	(28,896,787)	(4,605,407)
Ending Balance, shares at Sep. 30, 2019	2	844,468,378		1,122,311
Beginning Balance at Dec. 31, 2019	$ 5,217,800	$ 16,757,079		$ 22,000	2,412,969	(29,797,906)	(5,388,058)
Beginning Balance, shares at Dec. 31, 2019	2	844,468,378		1,122,311
Exercise of warrants in exchange for stock		$ 365,157			(365,157)
Exercise of warrants in exchange for stock, shares		9,941,623
Warrants issued for services - related parties					2,754,031		2,754,031
Warrants issued for services					50,763		50,763
Contributed capital - related party					17,495		17,495
Imputed interest - related party					38,981		38,981
Net loss						(4,313,294)	(4,313,294)
Ending Balance at Sep. 30, 2020	$ 5,217,800	$ 17,122,236		$ 22,000	4,909,082	(34,111,200)	(6,840,082)
Ending Balance, shares at Sep. 30, 2020	2	854,410,001		1,122,311
Beginning Balance at Jun. 30, 2020	$ 5,217,800	$ 16,757,079		$ 22,000	5,107,560	(33,418,042)	(6,313,603)
Beginning Balance, shares at Jun. 30, 2020	2	844,468,378		1,122,311
Exercise of warrants in exchange for stock		$ 365,157			(365,157)
Exercise of warrants in exchange for stock, shares		9,941,623
Warrants issued for services - related parties					141,620		141,620
Warrants issued for services					8,050		8,050
Imputed interest - related party					17,009		17,009
Net loss						(693,158)	(693,158)
Ending Balance at Sep. 30, 2020	$ 5,217,800	$ 17,122,236		$ 22,000	$ 4,909,082	$ (34,111,200)	$ (6,840,082)
Ending Balance, shares at Sep. 30, 2020	2	854,410,001		1,122,311

Condensed Consolidated Statem_3

Condensed Consolidated Statement of Changes in Stockholders Deficit (Parenthetical) - shares	Jul. 30, 2020	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Statement of Stockholders' Equity [Abstract]
Exercise of warrants	9,941,623	10,000,000	9,000,000	10,000,000	9,000,000

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash Flows From Operating Activities:
Net Loss	$ (4,313,294)	$ (2,008,731)
Adjustments to reconcile net loss to net cash used in operations
Depreciation expense	21,277	22,448
Imputed interest - related party	38,981	16,027
Fair value of options issued for services	2,804,794	584,776
Warrants issued/(cancelled) to consultants		(19,915)
Decrease (Increase) in prepaid expenses	18,766	(5,812)
Operating lease right-of-use, net	87,806	58,123
Increase in accrued expenses and other payables - related party	469,268	541,175
(Decrease) Increase in royalty agreement payable - related party
(Decrease)Increase in accounts payable	(40,538)	95,927
Operating lease liabilities, current	(81,617)	(53,601)
Net Cash Used In Operating Activities	(994,557)	(769,583)
Cash Flows From Investing Activities:
Purchase of Fixed Assets and Leasehold Improvements		(72,966)
Net Cash Used In Investing Activities		(72,966)
Cash Flows From Financing Activities:
Proceeds from Notes Payable - related party	850,000	120,000
Principal payments on debt	(45,000)	(8,000)
Contributed capital - related party	17,495
Proceeds from SBA Paycheck Protection Loan	90,100
Proceeds from issuance of common stock		1,000,000
Net Cash Provided by Financing Activities	912,595	1,112,000
Net Increase (Decrease) in Cash	(81,962)	269,451
Cash at Beginning of Period	125,024	13,697
Cash at End of Period	43,062	283,148
Supplemental disclosure of cash flow information:
Cash paid for interest
Cash paid for taxes
Supplemental disclosure of non-cash investing and financing activities:
Shares issued in connection with cashless warrants exercise	365,157	329,622
Settlement of accounts payable with note payable		265,244
Settlement of accounts payable with stock issuance		281,659
Adoption of lease standard ASC 842		$ 559,568

Summary of Significant Accounti

Summary of Significant Accounting Policies and Organization	9 Months Ended
	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Summary of Significant Accounting Policies and Organization	NOTE 1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (A) Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in The United States of America and the rules and regulations of the Securities and Exchange Commission for interim financial information. Accordingly, they do not include all the information necessary for a comprehensive presentation of financial position and results of operations. It is management’s opinion, however that all material adjustments (consisting of normal recurring adjustments) have been made which are necessary for a fair financial statements presentation. The results for the interim period are not necessarily indicative of the results to be expected for the year. Kraig Biocraft Laboratories, Inc. (the “Company”) was incorporated under the laws of the State of Wyoming on April 25, 2006. The Company was organized to develop high strength, protein based fiber, using recombinant DNA technology, for commercial applications in the textile and specialty fiber industries. (B) Foreign Currency The assets and liabilities of Prodigy Textiles, Co., Ltd. (the Company’s Vietnamese subsidiary) whose functional currency is the Vietnamese Dong, are translated into US dollars at period-end exchange rates prior to consolidation. Income and expense items are translated at the average rates of exchange prevailing during the period. The adjustments resulting from translating the Company’s financial statements are reflected as a component of other comprehensive (loss) income. Foreign currency transaction gains and losses are recognized in net earnings based on differences between foreign exchange rates on the transaction date and settlement date. (C) Use of Estimates In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates. (D) Cash For the purposes of the cash flow statements, the Company considers all highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents. There were no cash equivalents as of September 30, 2020 or December 31, 2019. (E) Loss Per Share Basic and diluted net loss per common share is computed based upon the weighted average common shares outstanding as defined by the Financial Accounting Standards Board (“FASB” Accounting Standards Codification (“ASC”) No. 260, “Earnings per Share.” For September 30, 2020 and September 30, 2019, warrants were not included in the computation of income/ (loss) per share because their inclusion is anti-dilutive. The computation of basic and diluted loss per share for September 30, 2020 and September 30, 2019 excludes the common stock equivalents of the following potentially dilutive securities because their inclusion would be anti-dilutive: September 30, 2020 September 30, 2019 Stock Warrants (Exercise price - $0.001/share) 45,995,917 57,995,917 Stock Options (Exercise price - $0.1150/Share) 27,340,000 - Convertible Preferred Stock 2 2 Total 73,335,919 57,995,919 (F) Research and Development Costs The Company expenses all research and development costs as incurred for which there is no alternative future use. These costs also include the expensing of employee compensation and employee stock based compensation. (G) Income Taxes The Company accounts for income taxes under FASB Codification Topic 740-10-25 (“ASC 740-10-25”). Under ASC No. 740-10-25, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC No. 740-10-25, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. On December 22, 2017, the 2017 Tax Cuts and Jobs Act (the “Tax Act”) was enacted into law and the new legislation contains several key tax provisions that affected us, including a one-time mandatory transition tax on accumulated foreign earnings and a reduction of the corporate income tax rate to 21% effective January 1, 2018, among others. We are required to recognize the effect of the tax law changes in the period of enactment, such as determining the transition tax, remeasuring our U.S. deferred tax assets and liabilities as well as reassessing the net realizability of our deferred tax assets and liabilities. In December 2017, the SEC staff issued Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act Effective January 1, 2009, the Company adopted guidance regarding accounting for uncertainty in income taxes. This guidance clarifies the accounting for income taxes by prescribing the minimum recognition threshold an income tax position is required to meet before being recognized in the financial statements and applies to all federal or state income tax positions. Each income tax position is assessed using a two-step process. A determination is first made as to whether it is more likely than not that the income tax position will be sustained, based upon technical merits, upon examination by the taxing authorities. If the income tax position is expected to meet the more likely than not criteria, the benefit recorded in the financial statements equals the largest amount that is greater than 50% likely to be realized upon its ultimate settlement. As of September 30, 2020 and December 31, 2019 there were no amounts that had been accrued in respect to uncertain tax positions. Fair value accounting requires bifurcation of embedded derivative instruments such as conversion features in convertible debt or equity instruments, and measurement of their fair value for accounting purposes. In determining the appropriate fair value, the Company uses the Black-Scholes option-pricing model. In assessing the convertible debt instruments, management determines if the convertible debt host instrument is conventional convertible debt and further if there is a beneficial conversion feature requiring measurement. If the instrument is not considered conventional convertible debt, the Company will continue its evaluation process of these instruments as derivative financial instruments. Once determined, derivative liabilities are adjusted to reflect fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives. In addition, the fair value of freestanding derivative instruments such as warrants, are also valued using the Black-Scholes option-pricing model. (H) Stock-Based Compensation The Company accounts for stock-based compensation for employees and directors in accordance with ASC 718, Compensation (“ASC 718”). ASC 718 requires all share-based payments to employees, including grants of employee stock options, to be recognized in the statement of operations based on their fair values. Under the provisions of ASC 718, stock-based compensation costs are measured at the grant date, based on the fair value of the award, and are recognized as expense over the employee’s requisite service period (generally the vesting period of the equity grant). The fair value of the Company’s common stock options are estimated using the Black Scholes option-pricing model with the following assumptions: expected volatility, dividend rate, risk free interest rate and the expected life. The Company expenses stock-based compensation by using the straight-line method. In accordance with ASC 718 and, excess tax benefits realized from the exercise of stock-based awards are classified as cash flows from operating activities. All excess tax benefits and tax deficiencies (including tax benefits of dividends on share-based payment awards) are recognized as income tax expense or benefit in the condensed consolidated statements of operations. The Company accounts for stock-based compensation awards issued to non-employees for services, as prescribed by ASC 718-10, at either the fair value of the services rendered or the instruments issued in exchange for such services, whichever is more readily determinable, using the measurement date guidelines enumerated in ASU 2018-07. (I) Recent Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, “Leases” Topic 842, which amends the guidance in former ASC Topic 840, Leases All other newly issued accounting pronouncements but not yet effective have been deemed either immaterial or not applicable. (J) Equipment The Company values property and equipment at cost and depreciates these assets using the straight-line method over their expected useful life. The Company uses a five year life for automobiles. In accordance with FASB ASC No. 360, Property, Plant and Equipment, There were no impairment losses recorded for the nine months ended September 30, 2020 and 2019. (K) Fair Value of Financial Instruments We hold certain financial assets, which are required to be measured at fair value on a recurring basis in accordance with the Statement of Financial Accounting Standard No. 157, “Fair Value Measurements” The three levels of the fair value hierarchy under ASC Topic 820-10 are described below: ● Level 1 - Valuations based on quoted prices in active markets for identical assets or liabilities that an entity has the ability to access. We believe our carrying value of level 1 instruments approximate their fair value at September 30, 2020 and December 31, 2019. ● Level 2 - Valuations based on quoted prices for similar assets or liabilities, quoted prices for identical assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities. ● Level 3 - Valuations based on inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. We consider depleting assets, asset retirement obligations and net profit interest liability to be Level 3. We determine the fair value of Level 3 assets and liabilities utilizing various inputs, including NYMEX price quotations and contract terms. September 30, 2020 December 31, 2019 Level 1 $ - $ - Level 2 $ - $ - Level 3 $ - $ - Total $ - $ - (L) Revenue Recognition The Company’s revenues have been generated primarily from a contract with the U.S. Government. The Company performed work under a cost-plus-fixed-fee contract. Under the base phase of that contract, the Company produced recombinant spider silk woven into ballistic shootpack panels. Those shootpack panels were delivered to the U.S. Government customer. Under an option period award starting in July 2017, to that original contract, the Company worked to develop new recombinant silks. Effective January 1, 2018, the Company adopted ASC No. 606 — Revenue from Contracts with Customers. Under ASC No. 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. For the three and nine months ended September 30, 2020 and 2019, the Company recognized $0 and $0 respectively in revenue from the Government contract. These revenues were generated for work performed in the development and production of the Company’s recombinant silks under the base and option period phases of our ongoing contract with the US Army. On July 24, 2017, the Company signed a contract option extension with the US Army to research and deliver recombinant spider silk fibers and threads. This contract option increased the total contract award by an additional $921,130 to a total of $1,021,092 and added 12 months to the contract duration. This effort was scheduled to end on September 24, 2018, but the Company requested an extension of this contract option period through April 2019 to complete the work. The Company has been in communication with the contracting office and is working with them as they determine the best path forward; Management believes there is a possibility of securing a follow-up contract to complete the delivery of all materials for the contract. The Company is also continuing to pursue additional contract opportunities with the Department of Defense, Department of Energy and other governmental agencies. (M) Concentration of Credit Risk The Company at times has cash in banks in excess of FDIC insurance limits. At September 30, 2020 and December 31, 2019, the Company had approximately $0 and $0, respectively in excess of FDIC insurance limits. For the three and nine months ended September 30, 2020 and 2019, the Company booked $0 and $0 for doubtful accounts.

Going Concern

Going Concern	9 Months Ended
	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	NOTE 2 GOING CONCERN As reflected in the accompanying financial statements, the Company has a working capital deficiency of $6,908,522 and stockholders’ deficiency of $6,840,082 and used $994,557 of cash in operations for nine months ended September 30, 2020. This raises substantial doubt about its ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company’s ability to raise additional capital and implement its business plan. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. Management believes that actions presently being taken to obtain additional funding and implement its strategic plans provide the opportunity for the Company to continue as a going concern.

Equipment

Equipment	9 Months Ended
	Sep. 30, 2020
Property, Plant and Equipment [Abstract]
Equipment	NOTE 3 EQUIPMENT At September 30, 2020 and December 31, 2019, property and equipment, net, is as follows: As of September 30, 2020 December 31, 2019 Automobile $ 41,805 $ 41,805 Laboratory Equipment 96,536 96,536 Office Equipment 7,260 7,260 Leasehold Improvements 85,389 85,389 Less: Accumulated Depreciation (134,946 ) (113,669 ) Total Property and Equipment, net $ 96,044 $ 117,321 Depreciation expense for the nine months ended September 30, 2020 and 2019, was $21,277 and $22,448, respectively Depreciation expense for the three months ended September 30, 2020 and 2019, was $8,159 and $9,045, respectively.

Right to Use Assets and Lease L

Right to Use Assets and Lease Liability	9 Months Ended
	Sep. 30, 2020
Right To Use Assets And Lease Liability
Right to Use Assets and Lease Liability	NOTE 4 - RIGHT TO USE ASSETS AND LEASE LIABILITITY Since September of 2015, we rent office space at 2723 South State Street, Suite 150, Ann Arbor, Michigan 48104, which is our principal place of business. We pay an annual rent of $2,508 for conference facilities, mail, fax, and reception services located at our principal place of business. On January 23, 2017 the Company signed an 8 year property lease with the Company’s President for land in Texas where the Company grows its mulberry. The Company pays a monthly rent of $960. Rent expense – related party for the nine months ended September 30, 2020 and 2019, was $9,819 and $11,913, respectively (See Note 9). On September 13, 2017, the Company signed a new two year lease commencing on October 1, 2017 and ending on September 30, 2019. The Company pays an annual rent of $39,200 for the year one of lease and $42,000 for the year two of lease for office and manufacturing space. On May 9, 2019 the Company signed a 5 year property lease with the Socialist Republic of Vietnam which consists of 4,560.57 square meters of space, which it leases at a current rent of approximately $45,150 per year one and two and with the 5% increase per year for years three through five. In February 2016, the FASB issued ASU 2016-02, “Leases” Topic 842, which amends the guidance in former ASC Topic 840, Leases The Company adopted the new lease guidance effective January 1, 2019 using the modified retrospective transition approach, applying the new standard to all of its leases existing at the date of initial application which is the effective date of adoption. Consequently, financial information will not be updated and the disclosures required under the new standard will not be provided for dates and periods before January 1, 2019. We elected the package of practical expedients which permits us to not reassess (1) whether any expired or existing contracts are or contain leases, (2) the lease classification for any expired or existing leases, and (3) any initial direct costs for any existing leases as of the effective date. We did not elect the hindsight practical expedient which permits entities to use hindsight in determining the lease term and assessing impairment. The adoption of the lease standard did not change our previously reported consolidated statements of operations and did not result in a cumulative catch-up adjustment to opening equity. The adoption of the new guidance resulted in the recognition of ROU assets of $529,135 and lease liabilities of $531,462. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. In calculating the present value of the lease payments, the Company elected to utilize its incremental borrowing rate based on the remaining lease terms as of the January 1, 2019 adoption date. This rate was determined to be 8% and the Company determined the initial present value, at inception, of $559,568. Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred, if any. The Company has elected the practical expedient to combine lease and non-lease components as a single component. The lease expense is recognized over the expected term on a straight-line basis. Operating leases are recognized on the balance sheet as right-of-use assets, current operating lease liabilities and non-current operating lease liabilities. The new standard also provides practical expedients and certain exemptions for an entity’s ongoing accounting. We have elected the short-term lease recognition exemption for all leases that qualify. This means, for those leases where the initial lease term is one year or less or for which the ROU asset at inception is deemed immaterial, we will not recognize ROU assets or lease liabilities. Those leases are expensed on a straight line basis over the term of the lease Right to use assets is summarized below: September 30, 2020 Right to use assets, net – related party $ 47,147 Right to use assets, net 41,136 Right to use assets, net 297,153 Total $ 385,436 During the nine months ended September 30, 2020, the Company recorded $72,428 as lease expense to current period operations. During the nine months ended September 30, 2020, the Company recorded $9,819 as lease expense – related party to current period operations. Lease liability is summarized below: September 30, 2020 Right to use liability, net – related party 49,466 Right to use liability, net 42,918 Right to use liability, net 305,958 Total 398,342 Less: short term portion $ (122,028 ) Long term position $ 276,314 Lease expense for the nine months ended September 30, 2020 was comprised of the following: Operating lease expense $ 33,866 Operating lease expense $ 34,743 Operating lease expense – related party $ 9,819

Accrued Interest - Related Part

Accrued Interest - Related Party	9 Months Ended
	Sep. 30, 2020
Accrued Interest - Related Party
Accrued Interest - Related Party	NOTE 5 ACCRUED INTEREST – RELATED PARTY On June 6, 2016, the Company received a $50,000 loan from our principal stockholder. Subsequently on December 1, 2017, the Company received an additional $30,000 loan from the same stockholder. On January 8, 2018 and March 31, 2018 the Company received an additional loan of $100,000 and $15,000, respectively. The Company received additional loan funds from the same stockholder as follows: $20,000 on April 26, 2018; $15,000 on June 21, 2018; $15,000 on June 29, 2018; $20,000 on July 5, 2018; $26,000 on October 1, 2018; $11,000 on October 12, 2018; $20,000 on December 21, 2018; $3,000 on January 4, 2019; $30,000 on January 17, 2019; $30,000 on February 1, 2019; $20,000 on February 15, 2019; $20,000 on March 1, 2019; $17,000 on January 4, 2019, $100,000 on November 20, 2019, $100,000 on December 18, 2019, $100,000 on January 24, 2020, $100,000 on February 19, 2020 $100,000 on March 9, 2020, $100,000 on April 8, 2020, $150,000 on June 3, 2020, $100,000 on July 16, 2020, $100,000 on August 12, 2020 and $100,000 on September 10, 2020. Pursuant to the terms of the loan, the advance bears an interest at 3%, is unsecured, and due on demand. Total loan payable to principal stockholder for as of December 31, 2019 is $642,000. Total loan payable to this principal stockholder as of September 30, 2020 is $1,492,000. During the nine months ended September 30, 2020, the Company recorded $38,981 as an in-kind contribution of interest related to the loan and recorded accrued interest payable of $24,485. During the nine months ended September 30, 2019, the Company recorded $16,027 as an in-kind contribution of interest related to the loan and recorded accrued interest payable of $10,624.

Note Payable

Note Payable	9 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Note Payable	NOTE 6 NOTE PAYABLE On March 1, 2019, the Company entered into an unsecured promissory note with Notre Dame - an unrelated party in the amount of $265,244 in exchange for outstanding account payable due to the debtor. Pursuant to the terms of the note, the note bears 10% interest per year from the date of default until the date the loan is paid in full. The term of the loan is twenty four months. The loan repayment commenced immediately over a twenty-four month period according to the following table. During the nine months ended September 30, 2020, the Company paid $45,000 of the loan balance (See Note 8 (A)): 1. $1,000 per month for the first six months; 2. $2,000 per month for the months seven and eight; 3. $5,000 per month for months nine through twenty three; and, 4. Final payment of all remaining balance, in the amount of $180,224 in month 24. On April 16, 2020, the Company, was granted a loan (the “Loan”) from The Huntington National Bank, in the aggregate amount of $90,100, pursuant to the Paycheck Protection Program (the “PPP”) under Division A, Title I of the CARES Act, which was enacted March 27, 2020. The Loan, which was in the form of a Note dated on or about April 16, 2020 issued by the Borrower, matures on or about April 16, 2022 and bears interest at an approximate rate of 1% per annum. The Note may be prepaid by the Borrower at any time prior to maturity with no prepayment penalties. Funds from the Loan may only be used for payroll costs, costs used to continue group health care benefits, mortgage payments, rent, utilities, and interest on other debt obligations incurred before February 15, 2020. The Company intends to use the entire Loan amount for qualifying expenses. Under the terms of the PPP, certain amounts of the Loan may be forgiven if they are used for qualifying expenses as described in the CARES Act.

Stockholders' Deficit

Stockholders' Deficit	9 Months Ended
	Sep. 30, 2020
Equity [Abstract]
Stockholders' Deficit	NOTE 7 STOCKHOLDERS’ DEFICIT (A) Common Stock Issued for Cash On March 9, 2019, the Company entered into a purchase agreement with one investor (the “Purchase Agreement”). Pursuant to the Purchase Agreement, the Company issued the investor 14,797,278 Units at a purchase price of $0.06758 per Unit, for total gross proceeds to the Company of $1,000,000. The Units consist of 14,797,278 shares of the Company’s Class A Common Stock (the “Common Stock”) and two warrants (the “Warrants”): (i) one warrant entitles the investor to purchase up to 14,797,278 shares of Common Stock at an exercise price of $0.06 per share (the “6 Cent Warrants”) and (ii) one warrant entitles the investor to purchase up to 7,398,639 shares of Common Stock at an exercise price of $0.08 per share (the “8 Cent Warrant”). The Warrants shall be exercisable at any time from the issuance date until the following expiration dates: ● ½ of all $0.06 Warrants shall expire on March 8, 2021; ● ½ of all $0.06 Warrants shall expire on March 8, 2022; ● ½ of all $0.08 Warrants shall expire on March 8, 2022; and, ● ½ of all $0.08 Warrants shall expire on March 8, 2023. (B) Common Stock Issued for Services Shares issued for services as mentioned below were valued at the closing price of the stock on the date of grant. On March 20, 2019, the Company issued 4,052,652 shares of its class A common stock with a fair value of $281,659 ($0.0695/share) on the date of settlement. The Company settled $243,159 of accounts payable to the University of Notre Dame. The Company recorded an additional amount of $38,500 based on the fair value of the shares on the date of settlement. See Note 8 (A). (C) Common Stock Warrants and Options On July 30, 2020, the Company issued 9,941,623 shares of Common stock in connection with the cashless exercise of 10,000,000 warrants. On February 19, 2020 the Company issued a 20-year option to purchase 20,000,000 shares of common stock at an exercise price of $0.115 per share to a related party for services rendered. The options had a fair value of $2,198,411, based upon the Black-Scholes option-pricing model on the date of grant and are fully vested on the date granted. Options will be exercisable on February 19, 2025, and for a period of 15 years expiring on February 19, 2040. During the nine months ended September 30, 2020, the Company recorded $2,198,411 as an expense for options issued. Expected dividends 0 % Expected volatility 125.19 % Expected term 3 years Risk free interest rate 1.56 % Expected forfeitures 0 % On February 19, 2020 the Company issued a 10-year option to purchase 6,000,000 shares of common stock at an exercise price of $0.115 per share to a related party for services rendered. The options had a fair value of $626,047, based upon the Black-Scholes option-pricing model on the date of grant and 2,000,000 options are fully vested on the date granted and 1,000,000 options vest at the end of each successive year for four years. Options will be exercisable on February 19, 2021, and for a period of 10 years expiring on February 19, 2030. During the nine months ended September 30, 2020, the Company recorded $272,673 as an expense for options issued. Expected dividends 0 % Expected volatility 125.19 % Expected term 3 years Risk free interest rate 1.50 % Expected forfeitures 0 % On February 19, 2020 the Company issued a 7-year option to purchase 1,340,000 shares of common stock at an exercise price of $0.115 per share to employees for services rendered. The options had a fair value of $133,063, based upon the Black-Scholes option-pricing model on the date of grant and 268,000 options are fully vested on the date granted and the remaining option vest equally over the remaining 4 years at the end of each successive year. Options will be exercisable on February 19, 2021, and for a period of 6 years expiring on February 19, 2027. During the nine months ended September 30, 2020, the Company recorded $40,935 as an expense for options issued. Expected dividends 0 % Expected volatility 125.19 % Expected term 6 years Risk free interest rate 1.46 % Expected forfeitures 0 % On September 26, 2019, the Company issued 766,667 shares in connection with the cashless exercise of the 1,000,000 warrants. On August 14, 2019, the Company issued 7,967,871 shares in connection with the cashless exercise of the 8,000,000 warrants. On August 8, 2019, the Company issued a 2-year option to purchase 2,000,000 shares of common stock at an exercise price of $0.2299 per share to a related party for services rendered. The options had a fair value of $267,574, based upon the Black-Scholes option-pricing model on the date of grant and are fully vested on the date granted. Options will be exercisable on August 8, 2020, and for a period of 3 years expiring on August 8, 2024. During the year ended December 31, 2019, the Company recorded $267,574 as an expense for options issued. Expected dividends 0 % Expected volatility 105.73 % Expected term 2 years Risk free interest rate 1.62 % Expected forfeitures 0 % On August 8, 2019, the Company issued a 2-year option to purchase 2,000,000 shares of common stock at an exercise price of $0.2299 per share to a related party for services rendered. The options had a fair value of $267,574, based upon the Black-Scholes option-pricing model on the date of grant and is fully vested on August 8, 2020. Options will be exercisable on August 8, 2022, and for a period of 3 years expiring on August 8, 2025. During the nine months ended September 30, 2020, the Company recorded $161,568 as an expense for options issued. Expected dividends 0 % Expected volatility 105.73 % Expected term 2 years Risk free interest rate 1.62 % Expected forfeitures 0 % On August 8, 2019, the Company issued a 3-year option to purchase 2,000,000 shares of common stock at an exercise price of $0.2299 per share to a related party for services rendered. The options had a fair value of $291,842, based upon the Black-Scholes option-pricing model on the date of grant and is fully vested on August 8, 2021. Options will be exercisable on August 8, 2023, and for a period of 3 years expiring on August 8, 2026. During the nine months ended September 30, 2020, the Company recorded $109,391 as an expense for options issued. Expected dividends 0 % Expected volatility 105.73 % Expected term 3 years Risk free interest rate 1.54 % Expected forfeitures 0 % On August 8, 2019, the Company issued a 2-year option to purchase 1,000,000 shares of common stock at an exercise price of $0.2299 per share to a related party for services rendered. The options had a fair value of $118,874, based upon the Black-Scholes option-pricing model on the date of grant and are fully vested on the date granted. Options will be exercisable on August 8, 2020, and for a period of 3 years expiring on August 8, 2023. During the year ended December 31, 2019, the Company recorded $118,874 as an expense for options issued. Expected dividends 0 % Expected volatility 105.73 % Expected term 2 years Risk free interest rate 1.62 % Expected forfeitures 0 % On August 8, 2019, the Company issued a 2-year option to purchase 1,000,000 shares of common stock at an exercise price of $0.2299 per share to a related party for services rendered. The options had a fair value of $118,874, based upon the Black-Scholes option-pricing model on the date of grant and are fully vested on the date granted. Options will be exercisable on August 8, 2021, and for a period of 3 years expiring on August 8, 2024. During the year ended December 31, 2019, the Company recorded $118,874 as an expense for options issued. Expected dividends 0 % Expected volatility 105.73 % Expected term 2 years Risk free interest rate 1.62 % Expected forfeitures 0 % On August 8, 2019, the Company issued a 2-year option to purchase 125,000 shares of common stock at an exercise price of $0.2299 per share to an employee for services rendered. The options had a fair value of $14,859, based upon the Black-Scholes option-pricing model on the date of grant and are fully vested on the date granted. Options will be exercisable on August 8, 2020, and for a period of 3 years expiring on August 8, 2023. During the year ended December 31, 2019, the Company recorded $14,859, as an expense for options issued. Expected dividends 0 % Expected volatility 105.73 % Expected term 2 years Risk free interest rate 1.62 % Expected forfeitures 0 % On August 8, 2019, the Company issued a 2-year option to purchase 125,000 shares of common stock at an exercise price of $0.2299 per share to a related party for services rendered. The options had a fair value of $16,723, based upon the Black-Scholes option-pricing model on the date of grant and are fully vested on August 8, 2020. Options will be exercisable on August 8, 2022, and for a period of 3 years expiring on August 8, 2025. During the nine months ended September 30, 2020, the Company recorded $10,098, as an expense for options issued. Expected dividends 0 % Expected volatility 105.73 % Expected term 2 years Risk free interest rate 1.62 % Expected forfeitures 0 % On August 8, 2019, the Company issued a 2-year options to purchase 125,000 shares of common stock at an exercise price of $0.2299 per share to a related party for services rendered. The options had a fair value of $18,240, based upon the Black-Scholes option-pricing model on the date of grant and are fully vested on August 8, 2021. Options will be exercisable on August 8, 2023, and for a period of 3 years expiring on August 8, 2026. During the nine months ended September 30, 2020, the Company recorded $6,837, as an expense for options issued. Expected dividends 0 % Expected volatility 105.73 % Expected term 3 years Risk free interest rate 1.54 % Expected forfeitures 0 % On August 8, 2019, the Company issued a 2-year options to purchase 125,000 shares of common stock at an exercise price of $0.2299 per share to a related party for services rendered. The options had a fair value of $19,525, based upon the Black-Scholes option-pricing model on the date of grant and are fully vested on August 8, 2022. Options will be exercisable on August 8, 2024, and for a period of 3 years expiring on August 8, 2027. During the nine months ended September 30, 2020, the Company recorded $4,881, as an expense for options issued. Expected dividends 0 % Expected volatility 105.73 % Expected term 3 years Risk free interest rate 1.54 % Expected forfeitures 0 % On March 20, 2018, the Company issued a 4-year warrant to purchase 600,000 shares of common stock at an exercise price of $0.001 per share to a consultant for services rendered. The warrants had a fair value of $19,915, based upon the Black-Scholes option-pricing model on the date of grant and are fully vested on March 20, 2018. Warrants will be exercisable on March 20, 2019, and for a period of 3 years expiring on March 20, 2022. During the year ended December 31, 2019, the Company recorded $19,915 as an expense for warrants issued. On April 5, 2019, the Company cancelled 600,000 warrant issued to a consultant on February 20, 2018 in exchange for $6,000 cash payment. In addition the Company also recorded a $19,915 reduction to warrant expense related to the warrant cancellation. Expected dividends 0 % Expected volatility 97.56 % Expected term 4 years Risk free interest rate 2.65 % Expected forfeitures 0 % On September 26, 2019, the Company issued 766,667 shares in connection with the cashless exercise of the 1,000,000 warrants. On August 14, 2019, the Company issued 7,967,871 shares in connection with the cashless exercise of the 8,000,000 warrants. Number of Warrants Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in Years) Balance, December 31, 2019 55,395,917 2.77 Granted - - Exercised (10,000,000 ) - Cancelled/Forfeited - - Balance, September 30, 2020 45,395,917 2.02 Intrinsic Value $ 9,799,286 For the nine months ended September 30, 2020, the following warrants were outstanding: Exercise Price Warrants Weighted Average Aggregate $ 0.001 11,000,000 0.80 $ 4,326,000 $ 0.056 3,000,000 0.86 $ 618,000 $ 0.04 2,300,000 0.90 $ 473,800 $ 0.06 7,398,639 0.44 $ 1,524,120 $ 0.06 7,398,639 1.44 $ 1,524,120 $ 0.08 3,699,320 1.44 $ 762,060 $ 0.08 3,699,320 2.44 $ 762,060 $ 0.2299 8,500,000 4.63 $ 1,751,000 For the year ended December 31, 2019, the following warrants were outstanding: Exercise Price Warrants Weighted Average Aggregate $ 0.001 21,000,000 1.65 $ 4,069,800 $ 0.056 3,000,000 1.61 $ 387,600 $ 0.04 2,300,000 1.70 $ 445,740 $ 0.06 7,398,639 1.19 $ 1,433,856 $ 0.06 7,398,639 2.19 $ 1,433,856 $ 0.08 3,699,320 2.19 $ 716,928 $ 0.08 3,699,320 3.19 $ 719,928 $ 0.2299 8,500,000 5.39 $ 1,647,300 For the nine months ended September 30, 2020, the following options were outstanding: Weighted Average Exercise Options Options Remaining Price Outstanding Exercisable Contractual Life $ 0.115 - 22,267,800 22.8 (D) Amendment to Articles of Incorporation On February 16, 2009, the Company amended its articles of incorporation to amend the number and class of shares the Company is authorized to issue as follows: ● Common stock Class A, unlimited number of shares authorized, no par value ● Common stock Class B, unlimited number of shares authorized, no par value ● Preferred stock, unlimited number of shares authorized, no par value Effective December 17, 2013, the Company amended its articles of incorporation to designate a Series A no par value preferred stock. Two shares of Series A Preferred stock have been authorized. (E) Common Stock Issued for Debt None (F) Capital contribution – Related Party For the nine months ended September 30, 2020, the Company recorded $17,495 as contribution of capital by Chief Financial Officer.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 8 COMMITMENTS AND CONTINGENCIES On November 10, 2010, the Company entered into an employment agreement with its CEO, effective January 1, 2011 through the December 31, 2015. The term of the agreement is a five year period at an annual salary of $210,000. There is a 6% annual increase. For the year ending December 31, 2015, the annual salary was $281,027. The employee is also to receive a 20% bonus based on the annual based salary. Any stock, stock options bonuses have to be approved by the board of directors. On January 1, 2016 the agreement was renewed with the same terms for another 5 years with an annual salary of $297,889 for the year ended December 31, 2016. On January 1, 2017 the agreement renewed with the same terms for another 5 years, but with an annual salary of $315,764 for the year ended December 31, 2017. On January 1, 2019 the agreement renewed again with the same terms for another 5 years, but with an annual salary of $354,791 for the year ended December 31, 2019. On January 1, 2020 the agreement renewed again with the same terms for another 5 years, but with an annual salary of $376,078 for the year ended December 31, 2020. As of September 30, 2020 and December 31, 2019, the accrued salary balance is $2,710,706 and $2,535,203, respectively. (See Note 9). On January 20, 2015, the board of directors appointed Mr. Jonathan R. Rice as our Chief Operating Officer. Mr. Rice’s employment agreement has a term of one year and can be terminated by either the Company or Mr. Rice at any time. Under the employment agreement, Mr. Rice is entitled to an annual cash compensation of $120,000, which includes salary, health insurance, 401K retirement plan contributions, etc. The Company also agreed to reimburse Mr. Rice for his past educational expenses of approximately $11,000. In addition, Mr. Rice was issued a three-year warrant to purchase 2,000,000 shares of common stock of the Company at an exercise price of $0.001 per share (the “January 2015 Warrant”) pursuant to the employment agreement. Additionally, on May 28, 2015, the Company issued a three-year warrant to purchase 3,000,000 shares of common stock of the Company at an exercise price of $0.001 per share (the “May 20165 Warrant”) to Mr. Rice. The 2,000,000 share warrant fully vested on October 28, 2016. For the year ended December 31, 2015, the Company recorded $121,448 for the warrants issued to Mr. Rice. On January 14, 2016, the Company signed a new employment agreement with Mr. Rice. The employment agreement has a term of one year and can be terminated by either the Company or Mr. Rice at any time. Under the employment agreement, Mr. Rice is entitled to annual cash compensation of $140,000, which includes salary, health insurance, 401K retirement plan contributions, etc. In addition, Mr. Rice was issued a three-year warrant to purchase 6,000,000 shares of common stock of the Company at an exercise price of $0.001 per share pursuant to the employment agreement. On January 9, 2018, the Company extended the expiration date of the January 2015 warrant from January 19, 2018 to January 31, 2020, and on January 10, 2020 the Company extended the expiration date of the warrant to January 23, 2015 and on March 15, 2018, the Company signed an extension of its at-will employment agreement with its COO, extending the term to January 31, 2019. On March 25, 2019, the Company signed an extension of its at-will employment agreement with its COO, extending the term to January 1, 2020. On April 26, 2019, the Company signed an agreement to increase Mr. Rice’s base salary by $20,000 per year and issue a one-time $20,000 bonus. Additionally, on August 15, 2019, the Company signed an agreement to increase Mr. Rice’s base salary by an additional $20,000 per year. The salary increase and the bonus is accrued and to be paid in full earlier by the direction of the Board or upon the earlier of: ●The Company maintaining $6,000,000 or more in working capital, ●Upon the transfer of ownership of more than 50% of the Corporation’s voting share or an assignment for the benefit of creditors or bankruptcy, or ●Upon the fifth year anniversary of the salary increase and the bonus issuance. As of September 30, 2020 and December 31, 2019 the Company owes $95,467 and $64,352, respectively, to Mr. Rice for payroll payable. On October 21, 2019, the Company signed an agreement to increase Mr. Rice’s base salary by $20,000 per year (effective August 15, 2019). The salary increase is accrued and to be paid in full earlier by the direction of the Board or upon the earlier of: ●The Company maintaining $6,000,000 or more in working capital, ●Upon the transfer of ownership of more than 50% of the Corporation’s voting share or an assignment for the benefit of creditors or bankruptcy, or ●Upon the fifth year anniversary of the salary increase and the bonus issuance. On July 3, 2019, the board of directors appointed Mr. Kenneth Le as the Company’s Director of Government relations and President of Prodigy Textiles. Mr. Le’s employment agreement has a term of one year and can be terminated by either the Company or Mr. Rice at any time. Under the employment agreement, Mr. Le is entitled to annual cash compensation of $60,000. In addition, Mr. Le was issued two three-year warrants to purchase 2,000,000 shares of common stock of the Company at an exercise price of $0.2299 per share. As of September 30, 2020 and December 31, 2019, the accrued salary balance is $1,961 and $1,154, respectively. (A) License Agreement On May 8, 2006, the Company entered into a license agreement. Pursuant to the terms of the agreement, the Company paid a non- refundable license fee of $10,000. The Company will pay a license maintenance fee of $10,000 on the one year anniversary of this agreement and each year thereafter. The Company will pay an annual research fee of $13,700 with first payment due January 2007, then on each subsequent anniversary of the effective date commencing May 4, 2007. The annual research fees are accrued by the Company for future payment. Pursuant to the terms of the agreement the Company may be required to pay additional fees aggregating up to a maximum of $10,000 a year for patent maintenance and prosecution relating to the licensed intellectual property. On October 28, 2011, the Company entered into a license agreement with the University of Notre Dame. Under the agreement, the Company received exclusive and non-exclusive rights to certain spider silk technologies including commercial rights with the right to sublicense such intellectual property. In consideration of the licenses granted under the agreement, the Company agreed to issue to the University of Notre Dame 2,200,000 shares of its common stock and to pay a royalty of 2% of net sales. The license agreement has a term of 20 years which can be extended on an annual basis after that. It can be terminated by the University of Notre Dame if the Company defaults on its obligations under the agreement and fails to cure such default within 90 days of a written notice by the university. The Company can terminate the agreement upon a 90 day written notice subject to payment of a termination fee of $5,000 if the termination takes place within 2 years after its effectiveness, $10,000 if the termination takes place within 4 years after its effectiveness and $20,000 if the Agreement is terminated after 4 years. On May 5, 2017, the Company signed an addendum to that agreement relating to tangible property and project intellectual property. On March 1, 2019, the Company singed an addendum to that agreement. The Company entered into a separate loan agreement and promissory noted dated March 1, 2019 as a payment for expenses paid by the University prior to January 31, 2019 totaling $265,244 and issued 4,025,652 shares of Class A common stock with a fair value of $281,659 as payment of certain debt. In the event of default the license agreement will be terminated. During the nine months ended September 30, 2020, the Company paid $45,000 of the balance (See Notes 6). (B) Royalty and Research Agreements On May 1, 2008 the Company entered into a five year consulting agreement for research and development. Pursuant to the terms of the agreement, the Company will be required to pay $1,000 per month, or at the Company’s option, the consulting fee may be paid in the form of Company common stock based upon the greater of $0.05 per share or the average of the closing price of the Company’s shares over the five days preceding such stock issuance. On April 6, 2018, the Company issued 36,000 shares with a fair value of $1,076 ($0.0299/share) to a consultant as consideration for consulting fees owed from October 1, 2014 through December 31, 2019 of $21,000. The issuance of shares resulted in gain on settlement of accounts payable of $19,924. On April 1, 2018, the Company ended the consulting agreement and no additional compensation will be issued. (See Note 7 (B)). On December 26, 2006, the Company entered into an addendum to the intellectual property transfer agreement with Mr. Thompson, its CEO. In accordance with FASB ASC No 480, Distinguishing Liabilities from Equity, On December 30, 2015, the Company entered into a cooperative agreement for the research and pilot production of hybrid silkworms in Vietnam. Under this agreement, the Company will establish a subsidiary in Vietnam where it will develop and produce hybrid silkworms. On April 24, 2018, the Company announced that it had received its investment registration certificate for its new Vietnamese subsidiary Prodigy Textiles Co., Ltd. On May 1, 2018, the Company announced that it had received its enterprise registration certificate for its new Vietnamese subsidiary Prodigy Textiles Co., Ltd. (C) Consulting Agreement On February 20, 2018, the Company signed an agreement with a consultant to provide services. Under this agreement the consultant will receive a warrant for 600,000 shares of common stock and may be awarded additional warrants for up to 3,000,000 shares of common stock if performance metrics are achieved. On March 20, 2018, the Company issued a 4-year warrant to purchase 600,000 shares of common stock at an exercise price of $0.001 per share to a consultant for services rendered. The warrants had a fair value of $19,915, based upon the Black-Scholes option-pricing model on the date of grant and are fully vested on March 20, 2018. Warrants will be exercisable on March 20, 2019, and for a period of 3 years expiring on March 20, 2022. During the year ended December 31, 2018, the Company recorded $19,915 as an expense for warrants issued (See Note 7 (C)). On April 5, 2019, the Company cancelled 600,000 warrant issued to a consultant on February 20, 2018 in exchange for $6,000 cash payment. (D) Operating Lease Agreements Since September of 2015, we rent office space at 2723 South State Street, Suite 150, Ann Arbor, Michigan 48104, which is our principal place of business. We pay an annual rent of $2,508 for conference facilities, mail, fax, and reception services located at our principal place of business. On May 9, 2019 the Company signed a 5 year property lease Socialist Republic of Vietnam which consists of 4,560.57 square meters of space, which it leases at a current rent of approximately $45,150 per year one and two and with the 5% increase per year for years three through five. On January 23, 2017 the Company signed an 8 year property lease with the Company’s President for land in Texas where the Company grows its mulberry. The Company pays a monthly rent of $960. Rent expense – related party for the nine months ended September 30, 2020 and 2019, was $9,819 and $11,913, respectively (See Note 9). On September 13, 2017, the Company signed a new two year lease commencing on October 1, 2017 and ending on March 31, 2020. The Company pays an annual rent of $39,200 for the year one of lease and $42,000 for the year two of lease for office and manufacturing space. On September 5, 2019, the Company signed a new two-year lease for this 5,000 square foot property in Lansing, MI that commenced on October 1, 2019 and ends on September 30, 2021, for its research and development headquarters. The Company pays an annual rent of $42,000 for year one of the lease and $44,800 for year two of the lease.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2020
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 9 RELATED PARTY TRANSACTIONS On December 26, 2006, the Company entered into an addendum to the intellectual property transfer agreement with Mr. Thompson, its CEO. Pursuant to the addendum, the Company agreed to issue either 200,000 preferred shares with the following preferences; no dividends and voting rights equal to 100 common shares per share of preferred stock or the payment of $120,000, the officer agreed to terminate the royalty payments due under the agreement and give title to the exclusive license for the non-protective apparel use of the intellectual property to the Company. On the date of the agreement, the Company did not have any preferred stock authorized with the required preferences. In accordance with FASB ASC No. 480, Distinguishing Liabilities from Equity On November 10, 2010, the Company entered into an employment agreement, with its CEO, effective January 1, 2011 through the December 31, 2015. Subsequently, on January 1, 2018 the agreement renewed with the same terms for another 5 years with an annual salary of $334,708 for the year ended December 31, 2019. As of September 30, 2020 and December 31, 2019, the accrued salary balance is $2,710,706 and $2,535,203, respectively. On January 14, 2016 the Company signed a new employment agreement with Mr. Rice, the Company’s COO. The employment agreement has a term of one year and can be terminated by either the Company or Mr. Rice at any time. Under the employment agreement, Mr. Rice is entitled to annual cash compensation of $140,000, which includes salary, health insurance, 401K retirement plan contributions, etc. In addition, Mr. Rice was issued a three-year warrant to purchase 6,000,000 shares of common stock of the Company at an exercise price of $0.001 per share pursuant to the employment agreement. On January 9, 2018, the Company extended the expiration date of a warrant for 2,000,000 shares of common stock from January 19, 2018 to January 31, 2020 and on January 10, 2020, the Company extended the expiration date of the warrant to January 23, 2015 for Mr. Rice. Additionally, on March 15, 2018, the Company signed an extension of its at-will employment agreement with its COO. On April 26, 2019, the Company signed an agreement to increase Mr. Rice’s base salary by $20,000 per year and issue a one-time $20,000 bonus. Additional, on August 15, 2019, the Company signed an agreement to increase Mr. Rice’s base salary by an additional $20,000 per year. The salary increase and the bonus is accrued and to be paid in full earlier by the direction of the Board or upon the earlier of: ● The Company maintaining $6,000,000 or more in working capital, ● Upon the transfer of ownership of more than 50% of the Corporation’s voting share or an assignment for the benefit of creditors or bankruptcy, or ● Upon the fifth year anniversary of the salary increase and the bonus issuance. As of September 30, 2020 and December 31, 2019, the Company owes $95,467 and $64,351, respectively, to Mr. Rice for payroll payable. On July 3, 2019, the board of directors appointed Mr. Kenneth Le as the Company’s Director of Government relations and President of Prodigy Textiles. Mr. Le’s employment agreement has a term of one year and can be terminated by either the Company or Mr. Rice at any time. Under the employment agreement, Mr. Le is entitled to an annual cash compensation of $60,000. In addition, Mr. Le was issued two three-year warrants to purchase 2,000,000 shares of common stock of the Company at an exercise price of $0.2299 per share. As of September 30, 2020 and December 31, 2019, the accrued salary balance is $1,961 and $1,154, respectively. On June 6, 2016, the Company received a $50,000 loan from our principal stockholder. Subsequently on December 1, 2017, the Company received an additional $30,000 loan from the same stockholder. On January 8, 2018 and March 31, 2018 the Company received an additional loan of $100,000 and $15,000, respectively. The Company received additional loan funds from the same stockholder as follows: $20,000 on April 26, 2018; $15,000 on June 21, 2018; $15,000 on June 29, 2018; $20,000 on July 5, 2018; $26,000 on October 1, 2018; $11,000 on October 12, 2018; $20,000 on December 21, 2018; $3,000 on January 4, 2019; $30,000 on January 17, 2019; $30,000 on February 1, 2019; $20,000 on February 15, 2019; $20,000 on March 1, 2019; $17,000 on January 4, 2019, $100,000 on November 20, 2019, $100,000 on December 18, 2019, $100,000 on January 24, 2020, $100,000 on February 19, 2020, $100,000 on April 8, 2020, $150,000 on June 3, 2020, $100,000 on July 16, 2020, $100,000 on August 12, 2020 and $100,000 on September 10, 2020. Pursuant to the terms of the loan, the advance bears an interest at 3%, is unsecured, and due on demand. Total loan payable to principal stockholder for as of December 31, 2019 is $642,000. Total loan payable to this principal stockholder as of September 30, 2020 is $1,492,000. During the nine months ended September 30, 2020, the Company recorded $38,981 as an in-kind contribution of interest related to the loan and recorded accrued interest payable of $24,485. During the nine months ended September 30, 2019, the Company recorded $16,027 as an in-kind contribution of interest related to the loan and recorded accrued interest payable of $10,624. On January 23, 2017, the Company signed an 8 year property lease with the Company’s President for land in Texas. The Company pays $960 per month starting on February 1, 2017 and uses this facility to grow mulberry for its U.S. silk operations. Rent expense – related party for nine months ended September 30, 2020 and 2019 was $9,819 and $11,913, respectively. As of September 30, 2020 and December 31, 2019, there was $325,516 and $304,539, respectively, included in accounts payable and accrued expenses - related party, which is owed to the Company’s Chief Executive Officer and Chief Operations Officer. As of September 30, 2020, there was $1,411,414 of accrued interest- related party and $69,669 in shareholder loan interest – related party included in accounts payable and accrued expenses – related party, which is owed to the Company’s Chief Executive officer. As of December 31, 2019, there was $1,196,503 of accrued interest- related party and $43,715 in shareholder loan interest – related party included in accounts payable and accrued expenses – related party, which is owed to the Company’s Chief Executive officer. As of September 30, 2020, the Company owes $2,710,706 in accrued salary to principal stockholder, $95,467 to the Company’s COO, $1,962 to Director of Prodigy Textiles and $22,900 to its office employees. As of December 31, 2019, the Company owes $2,535,203 in accrued salary to principal stockholder, $64,351 to the Company’s COO, $1,153 to Director of Prodigy Textiles and $4,477 to its office employees. The Company owes $65,292 in royalty payable to related party as of September 30, 2020 and December 31, 2019.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2020
Subsequent Events [Abstract]
Subsequent Events	NOTE 10 SUBSEQUENT EVENTS The Company has analyzed its operations subsequent to November 10, 2020 through the date these financial statements were issued, and has determined that, other than disclosed below, it does not have any material subsequent events to disclose. On November 4, 2020, the Company received $30,000 from a principal stockholder. Pursuant to the terms of the loan, the advanced bear an interest at 3%, is unsecured and due on demand.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies and Organization (Policies)	9 Months Ended
	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	(A) Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in The United States of America and the rules and regulations of the Securities and Exchange Commission for interim financial information. Accordingly, they do not include all the information necessary for a comprehensive presentation of financial position and results of operations. It is management’s opinion, however that all material adjustments (consisting of normal recurring adjustments) have been made which are necessary for a fair financial statements presentation. The results for the interim period are not necessarily indicative of the results to be expected for the year. Kraig Biocraft Laboratories, Inc. (the “Company”) was incorporated under the laws of the State of Wyoming on April 25, 2006. The Company was organized to develop high strength, protein based fiber, using recombinant DNA technology, for commercial applications in the textile and specialty fiber industries.
Foreign Currency	(B) Foreign Currency The assets and liabilities of Prodigy Textiles, Co., Ltd. (the Company’s Vietnamese subsidiary) whose functional currency is the Vietnamese Dong, are translated into US dollars at period-end exchange rates prior to consolidation. Income and expense items are translated at the average rates of exchange prevailing during the period. The adjustments resulting from translating the Company’s financial statements are reflected as a component of other comprehensive (loss) income. Foreign currency transaction gains and losses are recognized in net earnings based on differences between foreign exchange rates on the transaction date and settlement date.
Use of Estimates	(C) Use of Estimates In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates.
Cash	(D) Cash For the purposes of the cash flow statements, the Company considers all highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents. There were no cash equivalents as of September 30, 2020 or December 31, 2019.
Loss Per Share	(E) Loss Per Share Basic and diluted net loss per common share is computed based upon the weighted average common shares outstanding as defined by the Financial Accounting Standards Board (“FASB” Accounting Standards Codification (“ASC”) No. 260, “Earnings per Share.” For September 30, 2020 and September 30, 2019, warrants were not included in the computation of income/ (loss) per share because their inclusion is anti-dilutive. The computation of basic and diluted loss per share for September 30, 2020 and September 30, 2019 excludes the common stock equivalents of the following potentially dilutive securities because their inclusion would be anti-dilutive: September 30, 2020 September 30, 2019 Stock Warrants (Exercise price - $0.001/share) 45,995,917 57,995,917 Stock Options (Exercise price - $0.1150/Share) 27,340,000 - Convertible Preferred Stock 2 2 Total 73,335,919 57,995,919
Research and Development Costs	F) Research and Development Costs The Company expenses all research and development costs as incurred for which there is no alternative future use. These costs also include the expensing of employee compensation and employee stock based compensation.
Income Taxes	(G) Income Taxes The Company accounts for income taxes under FASB Codification Topic 740-10-25 (“ASC 740-10-25”). Under ASC No. 740-10-25, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC No. 740-10-25, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. On December 22, 2017, the 2017 Tax Cuts and Jobs Act (the “Tax Act”) was enacted into law and the new legislation contains several key tax provisions that affected us, including a one-time mandatory transition tax on accumulated foreign earnings and a reduction of the corporate income tax rate to 21% effective January 1, 2018, among others. We are required to recognize the effect of the tax law changes in the period of enactment, such as determining the transition tax, remeasuring our U.S. deferred tax assets and liabilities as well as reassessing the net realizability of our deferred tax assets and liabilities. In December 2017, the SEC staff issued Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act Effective January 1, 2009, the Company adopted guidance regarding accounting for uncertainty in income taxes. This guidance clarifies the accounting for income taxes by prescribing the minimum recognition threshold an income tax position is required to meet before being recognized in the financial statements and applies to all federal or state income tax positions. Each income tax position is assessed using a two-step process. A determination is first made as to whether it is more likely than not that the income tax position will be sustained, based upon technical merits, upon examination by the taxing authorities. If the income tax position is expected to meet the more likely than not criteria, the benefit recorded in the financial statements equals the largest amount that is greater than 50% likely to be realized upon its ultimate settlement. As of September 30, 2020 and December 31, 2019 there were no amounts that had been accrued in respect to uncertain tax positions. Fair value accounting requires bifurcation of embedded derivative instruments such as conversion features in convertible debt or equity instruments, and measurement of their fair value for accounting purposes. In determining the appropriate fair value, the Company uses the Black-Scholes option-pricing model. In assessing the convertible debt instruments, management determines if the convertible debt host instrument is conventional convertible debt and further if there is a beneficial conversion feature requiring measurement. If the instrument is not considered conventional convertible debt, the Company will continue its evaluation process of these instruments as derivative financial instruments. Once determined, derivative liabilities are adjusted to reflect fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives. In addition, the fair value of freestanding derivative instruments such as warrants, are also valued using the Black-Scholes option-pricing model.
Stock-Based Compensation	(H) Stock-Based Compensation The Company accounts for stock-based compensation for employees and directors in accordance with ASC 718, Compensation (“ASC 718”). ASC 718 requires all share-based payments to employees, including grants of employee stock options, to be recognized in the statement of operations based on their fair values. Under the provisions of ASC 718, stock-based compensation costs are measured at the grant date, based on the fair value of the award, and are recognized as expense over the employee’s requisite service period (generally the vesting period of the equity grant). The fair value of the Company’s common stock options are estimated using the Black Scholes option-pricing model with the following assumptions: expected volatility, dividend rate, risk free interest rate and the expected life. The Company expenses stock-based compensation by using the straight-line method. In accordance with ASC 718 and, excess tax benefits realized from the exercise of stock-based awards are classified as cash flows from operating activities. All excess tax benefits and tax deficiencies (including tax benefits of dividends on share-based payment awards) are recognized as income tax expense or benefit in the condensed consolidated statements of operations. The Company accounts for stock-based compensation awards issued to non-employees for services, as prescribed by ASC 718-10, at either the fair value of the services rendered or the instruments issued in exchange for such services, whichever is more readily determinable, using the measurement date guidelines enumerated in ASU 2018-07.
Recent Accounting Pronouncements	(I) Recent Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, “Leases” Topic 842, which amends the guidance in former ASC Topic 840, Leases All other newly issued accounting pronouncements but not yet effective have been deemed either immaterial or not applicable.
Equipment	(J) Equipment The Company values property and equipment at cost and depreciates these assets using the straight-line method over their expected useful life. The Company uses a five year life for automobiles. In accordance with FASB ASC No. 360, Property, Plant and Equipment, There were no impairment losses recorded for the nine months ended September 30, 2020 and 2019.
Fair Value of Financial Instruments	(K) Fair Value of Financial Instruments We hold certain financial assets, which are required to be measured at fair value on a recurring basis in accordance with the Statement of Financial Accounting Standard No. 157, “Fair Value Measurements” The three levels of the fair value hierarchy under ASC Topic 820-10 are described below: ● Level 1 - Valuations based on quoted prices in active markets for identical assets or liabilities that an entity has the ability to access. We believe our carrying value of level 1 instruments approximate their fair value at September 30, 2020 and December 31, 2019. ● Level 2 - Valuations based on quoted prices for similar assets or liabilities, quoted prices for identical assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities. ● Level 3 - Valuations based on inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. We consider depleting assets, asset retirement obligations and net profit interest liability to be Level 3. We determine the fair value of Level 3 assets and liabilities utilizing various inputs, including NYMEX price quotations and contract terms. September 30, 2020 December 31, 2019 Level 1 $ - $ - Level 2 $ - $ - Level 3 $ - $ - Total $ - $ -
Revenue Recognition	(L) Revenue Recognition The Company’s revenues have been generated primarily from a contract with the U.S. Government. The Company performed work under a cost-plus-fixed-fee contract. Under the base phase of that contract, the Company produced recombinant spider silk woven into ballistic shootpack panels. Those shootpack panels were delivered to the U.S. Government customer. Under an option period award starting in July 2017, to that original contract, the Company worked to develop new recombinant silks. Effective January 1, 2018, the Company adopted ASC No. 606 — Revenue from Contracts with Customers. Under ASC No. 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. For the three and nine months ended September 30, 2020 and 2019, the Company recognized $0 and $0 respectively in revenue from the Government contract. These revenues were generated for work performed in the development and production of the Company’s recombinant silks under the base and option period phases of our ongoing contract with the US Army. On July 24, 2017, the Company signed a contract option extension with the US Army to research and deliver recombinant spider silk fibers and threads. This contract option increased the total contract award by an additional $921,130 to a total of $1,021,092 and added 12 months to the contract duration. This effort was scheduled to end on September 24, 2018, but the Company requested an extension of this contract option period through April 2019 to complete the work. The Company has been in communication with the contracting office and is working with them as they determine the best path forward; Management believes there is a possibility of securing a follow-up contract to complete the delivery of all materials for the contract. The Company is also continuing to pursue additional contract opportunities with the Department of Defense, Department of Energy and other governmental agencies.
Concentration of Credit Risk	(M) Concentration of Credit Risk The Company at times has cash in banks in excess of FDIC insurance limits. At September 30, 2020 and December 31, 2019, the Company had approximately $0 and $0, respectively in excess of FDIC insurance limits. For the three and nine months ended September 30, 2020 and 2019, the Company booked $0 and $0 for doubtful accounts.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies and Organization (Tables)	9 Months Ended
	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Antidilutive Securities of Earnings Per Share	The computation of basic and diluted loss per share for September 30, 2020 and September 30, 2019 excludes the common stock equivalents of the following potentially dilutive securities because their inclusion would be anti-dilutive: September 30, 2020 September 30, 2019 Stock Warrants (Exercise price - $0.001/share) 45,995,917 57,995,917 Stock Options (Exercise price - $0.1150/Share) 27,340,000 - Convertible Preferred Stock 2 2 Total 73,335,919 57,995,919
Schedule of Fair Value of Financial Instruments	September 30, 2020 December 31, 2019 Level 1 $ - $ - Level 2 $ - $ - Level 3 $ - $ - Total $ - $ -

Equipment (Tables)

Equipment (Tables)	9 Months Ended
	Sep. 30, 2020
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	At September 30, 2020 and December 31, 2019, property and equipment, net, is as follows: As of September 30, 2020 December 31, 2019 Automobile $ 41,805 $ 41,805 Laboratory Equipment 96,536 96,536 Office Equipment 7,260 7,260 Leasehold Improvements 85,389 85,389 Less: Accumulated Depreciation (134,946 ) (113,669 ) Total Property and Equipment, net $ 96,044 $ 117,321

Right to Use Assets and Lease_2

Right to Use Assets and Lease Liability (Tables)	9 Months Ended
	Sep. 30, 2020
Right To Use Assets And Lease Liability
Schedule of Right Use of Assets	Right to use assets is summarized below: September 30, 2020 Right to use assets, net – related party $ 47,147 Right to use assets, net 41,136 Right to use assets, net 297,153 Total $ 385,436
Schedule of Lease Liability	Lease liability is summarized below: September 30, 2020 Right to use liability, net – related party 49,466 Right to use liability, net 42,918 Right to use liability, net 305,958 Total 398,342 Less: short term portion $ (122,028 ) Long term position $ 276,314
Schedule of Lease Cost	Lease expense for the nine months ended September 30, 2020 was comprised of the following: Operating lease expense $ 33,866 Operating lease expense $ 34,743 Operating lease expense – related party $ 9,819

Stockholders' Deficit (Tables)

Stockholders' Deficit (Tables)	9 Months Ended
	Sep. 30, 2020
Equity [Abstract]
Schedule of Option Assumption	On February 19, 2020 the Company issued a 20-year option to purchase 20,000,000 shares of common stock at an exercise price of $0.115 per share to a related party for services rendered. The options had a fair value of $2,198,411, based upon the Black-Scholes option-pricing model on the date of grant and are fully vested on the date granted. Options will be exercisable on February 19, 2025, and for a period of 15 years expiring on February 19, 2040. During the nine months ended September 30, 2020, the Company recorded $2,198,411 as an expense for options issued. Expected dividends 0 % Expected volatility 125.19 % Expected term 3 years Risk free interest rate 1.56 % Expected forfeitures 0 % On February 19, 2020 the Company issued a 10-year option to purchase 6,000,000 shares of common stock at an exercise price of $0.115 per share to a related party for services rendered. The options had a fair value of $626,047, based upon the Black-Scholes option-pricing model on the date of grant and 2,000,000 options are fully vested on the date granted and 1,000,000 options vest at the end of each successive year for four years. Options will be exercisable on February 19, 2021, and for a period of 10 years expiring on February 19, 2030. During the nine months ended September 30, 2020, the Company recorded $272,673 as an expense for options issued. Expected dividends 0 % Expected volatility 125.19 % Expected term 3 years Risk free interest rate 1.50 % Expected forfeitures 0 % On February 19, 2020 the Company issued a 7-year option to purchase 1,340,000 shares of common stock at an exercise price of $0.115 per share to employees for services rendered. The options had a fair value of $133,063, based upon the Black-Scholes option-pricing model on the date of grant and 268,000 options are fully vested on the date granted and the remaining option vest equally over the remaining 4 years at the end of each successive year. Options will be exercisable on February 19, 2021, and for a period of 6 years expiring on February 19, 2027. During the nine months ended September 30, 2020, the Company recorded $40,935 as an expense for options issued. Expected dividends 0 % Expected volatility 125.19 % Expected term 6 years Risk free interest rate 1.46 % Expected forfeitures 0 % On September 26, 2019, the Company issued 766,667 shares in connection with the cashless exercise of the 1,000,000 warrants. On August 14, 2019, the Company issued 7,967,871 shares in connection with the cashless exercise of the 8,000,000 warrants. On August 8, 2019, the Company issued a 2-year option to purchase 2,000,000 shares of common stock at an exercise price of $0.2299 per share to a related party for services rendered. The options had a fair value of $267,574, based upon the Black-Scholes option-pricing model on the date of grant and are fully vested on the date granted. Options will be exercisable on August 8, 2020, and for a period of 3 years expiring on August 8, 2024. During the year ended December 31, 2019, the Company recorded $267,574 as an expense for options issued. Expected dividends 0 % Expected volatility 105.73 % Expected term 2 years Risk free interest rate 1.62 % Expected forfeitures 0 % On August 8, 2019, the Company issued a 2-year option to purchase 2,000,000 shares of common stock at an exercise price of $0.2299 per share to a related party for services rendered. The options had a fair value of $267,574, based upon the Black-Scholes option-pricing model on the date of grant and is fully vested on August 8, 2020. Options will be exercisable on August 8, 2022, and for a period of 3 years expiring on August 8, 2025. During the nine months ended September 30, 2020, the Company recorded $161,568 as an expense for options issued. Expected dividends 0 % Expected volatility 105.73 % Expected term 2 years Risk free interest rate 1.62 % Expected forfeitures 0 % On August 8, 2019, the Company issued a 3-year option to purchase 2,000,000 shares of common stock at an exercise price of $0.2299 per share to a related party for services rendered. The options had a fair value of $291,842, based upon the Black-Scholes option-pricing model on the date of grant and is fully vested on August 8, 2021. Options will be exercisable on August 8, 2023, and for a period of 3 years expiring on August 8, 2026. During the nine months ended September 30, 2020, the Company recorded $109,391 as an expense for options issued. Expected dividends 0 % Expected volatility 105.73 % Expected term 3 years Risk free interest rate 1.54 % Expected forfeitures 0 % On August 8, 2019, the Company issued a 2-year option to purchase 1,000,000 shares of common stock at an exercise price of $0.2299 per share to a related party for services rendered. The options had a fair value of $118,874, based upon the Black-Scholes option-pricing model on the date of grant and are fully vested on the date granted. Options will be exercisable on August 8, 2020, and for a period of 3 years expiring on August 8, 2023. During the year ended December 31, 2019, the Company recorded $118,874 as an expense for options issued. Expected dividends 0 % Expected volatility 105.73 % Expected term 2 years Risk free interest rate 1.62 % Expected forfeitures 0 % On August 8, 2019, the Company issued a 2-year option to purchase 1,000,000 shares of common stock at an exercise price of $0.2299 per share to a related party for services rendered. The options had a fair value of $118,874, based upon the Black-Scholes option-pricing model on the date of grant and are fully vested on the date granted. Options will be exercisable on August 8, 2021, and for a period of 3 years expiring on August 8, 2024. During the year ended December 31, 2019, the Company recorded $118,874 as an expense for options issued. Expected dividends 0 % Expected volatility 105.73 % Expected term 2 years Risk free interest rate 1.62 % Expected forfeitures 0 % On August 8, 2019, the Company issued a 2-year option to purchase 125,000 shares of common stock at an exercise price of $0.2299 per share to an employee for services rendered. The options had a fair value of $14,859, based upon the Black-Scholes option-pricing model on the date of grant and are fully vested on the date granted. Options will be exercisable on August 8, 2020, and for a period of 3 years expiring on August 8, 2023. During the year ended December 31, 2019, the Company recorded $14,859, as an expense for options issued. Expected dividends 0 % Expected volatility 105.73 % Expected term 2 years Risk free interest rate 1.62 % Expected forfeitures 0 % On August 8, 2019, the Company issued a 2-year option to purchase 125,000 shares of common stock at an exercise price of $0.2299 per share to a related party for services rendered. The options had a fair value of $16,723, based upon the Black-Scholes option-pricing model on the date of grant and are fully vested on August 8, 2020. Options will be exercisable on August 8, 2022, and for a period of 3 years expiring on August 8, 2025. During the nine months ended September 30, 2020, the Company recorded $10,098, as an expense for options issued. Expected dividends 0 % Expected volatility 105.73 % Expected term 2 years Risk free interest rate 1.62 % Expected forfeitures 0 % On August 8, 2019, the Company issued a 2-year options to purchase 125,000 shares of common stock at an exercise price of $0.2299 per share to a related party for services rendered. The options had a fair value of $18,240, based upon the Black-Scholes option-pricing model on the date of grant and are fully vested on August 8, 2021. Options will be exercisable on August 8, 2023, and for a period of 3 years expiring on August 8, 2026. During the nine months ended September 30, 2020, the Company recorded $6,837, as an expense for options issued. Expected dividends 0 % Expected volatility 105.73 % Expected term 3 years Risk free interest rate 1.54 % Expected forfeitures 0 % On August 8, 2019, the Company issued a 2-year options to purchase 125,000 shares of common stock at an exercise price of $0.2299 per share to a related party for services rendered. The options had a fair value of $19,525, based upon the Black-Scholes option-pricing model on the date of grant and are fully vested on August 8, 2022. Options will be exercisable on August 8, 2024, and for a period of 3 years expiring on August 8, 2027. During the nine months ended September 30, 2020, the Company recorded $4,881, as an expense for options issued. Expected dividends 0 % Expected volatility 105.73 % Expected term 3 years Risk free interest rate 1.54 % Expected forfeitures 0 % On March 20, 2018, the Company issued a 4-year warrant to purchase 600,000 shares of common stock at an exercise price of $0.001 per share to a consultant for services rendered. The warrants had a fair value of $19,915, based upon the Black-Scholes option-pricing model on the date of grant and are fully vested on March 20, 2018. Warrants will be exercisable on March 20, 2019, and for a period of 3 years expiring on March 20, 2022. During the year ended December 31, 2019, the Company recorded $19,915 as an expense for warrants issued. On April 5, 2019, the Company cancelled 600,000 warrant issued to a consultant on February 20, 2018 in exchange for $6,000 cash payment. In addition the Company also recorded a $19,915 reduction to warrant expense related to the warrant cancellation. Expected dividends 0 % Expected volatility 97.56 % Expected term 4 years Risk free interest rate 2.65 % Expected forfeitures 0 %
Schedule of Warrants Activity	On August 14, 2019, the Company issued 7,967,871 shares in connection with the cashless exercise of the 8,000,000 warrants. Number of Warrants Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in Years) Balance, December 31, 2019 55,395,917 2.77 Granted - - Exercised (10,000,000 ) - Cancelled/Forfeited - - Balance, September 30, 2020 45,395,917 2.02 Intrinsic Value $ 9,799,286
Schedule of Warrants Outstanding	For the nine months ended September 30, 2020, the following warrants were outstanding: Exercise Price Warrants Weighted Average Aggregate $ 0.001 11,000,000 0.80 $ 4,326,000 $ 0.056 3,000,000 0.86 $ 618,000 $ 0.04 2,300,000 0.90 $ 473,800 $ 0.06 7,398,639 0.44 $ 1,524,120 $ 0.06 7,398,639 1.44 $ 1,524,120 $ 0.08 3,699,320 1.44 $ 762,060 $ 0.08 3,699,320 2.44 $ 762,060 $ 0.2299 8,500,000 4.63 $ 1,751,000 For the year ended December 31, 2019, the following warrants were outstanding: Exercise Price Warrants Weighted Average Aggregate $ 0.001 21,000,000 1.65 $ 4,069,800 $ 0.056 3,000,000 1.61 $ 387,600 $ 0.04 2,300,000 1.70 $ 445,740 $ 0.06 7,398,639 1.19 $ 1,433,856 $ 0.06 7,398,639 2.19 $ 1,433,856 $ 0.08 3,699,320 2.19 $ 716,928 $ 0.08 3,699,320 3.19 $ 719,928 $ 0.2299 8,500,000 5.39 $ 1,647,300
Schedule of Options Outstanding	For the nine months ended September 30, 2020, the following options were outstanding: Weighted Average Exercise Options Options Remaining Price Outstanding Exercisable Contractual Life $ 0.115 - 22,267,800 22.8

Summary of Significant Accoun_4

Summary of Significant Accounting Policies and Organization (Details Narrative) - USD ($)	Jan. 02, 2018	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Jul. 24, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash equivalents
Income tax rate, percentage	21.00%
Income tax, uncertain tax positions
Impairment losses on equipment
Revenue
Additional contract award							$ 921,130
Contract award							$ 1,021,092
Cash excess of FDIC insurance limits		0		0		$ 0
Doubtful accounts		$ 0	$ 0	$ 0	$ 0

Summary of Significant Accoun_5

Summary of Significant Accounting Policies and Organization - Schedule of Antidilutive Securities of Earnings Per Share (Details) - shares	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Antidilutive Securities	73,335,919	57,995,919
Stock Warrants [Member]
Antidilutive Securities	45,995,917	57,995,917
Stock Options [Member]
Antidilutive Securities	27,340,000
Convertible Preferred Stock [Member]
Antidilutive Securities	2	2

Summary of Significant Accoun_6

Summary of Significant Accounting Policies and Organization - Schedule of Antidilutive Securities of Earnings Per Share (Details) (Parenthetical) - $ / shares	Sep. 30, 2020	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Warrants exercise price	$ 0.001	$ 0.001
Option exercise price	$ 0.1150	$ 0.1150

Summary of Significant Accoun_7

Summary of Significant Accounting Policies and Organization - Schedule of Fair Value of Financial Instruments (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Fair value of assets and liabilities
Level 1 [Member]
Fair value of assets and liabilities
Level 2 [Member]
Fair value of assets and liabilities
Level 3 [Member]
Fair value of assets and liabilities

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Jun. 30, 2020	Dec. 31, 2019	Jun. 30, 2019	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Working capital	$ 6,908,522
Stockholders' deficiency	(6,840,082)	$ (4,605,407)	$ (6,313,603)	$ (5,388,058)	$ (4,067,265)	$ (4,459,223)
Cash used in operating activities	$ (994,557)	$ (769,583)

Equipment (Details Narrative)

Equipment (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 8,159	$ 9,045	$ 21,277	$ 22,448

Equipment - Schedule of Propert

Equipment - Schedule of Property and Equipment (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Less: Accumulated Depreciation	$ (134,946)	$ (113,669)
Total Property and Equipment, net	96,044	117,321
Automobile [Member]
Property and Equipment, gross	41,805	41,805
Laboratory Equipment [Member]
Property and Equipment, gross	96,536	96,536
Office Equipment [Member]
Property and Equipment, gross	7,260	7,260
Leasehold Improvements [Member]
Property and Equipment, gross	$ 85,389	$ 85,389

Right to Use Assets and Lease_3

Right to Use Assets and Lease Liability (Details Narrative)	May 09, 2019USD ($)ft²	Jan. 23, 2017USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2020USD ($)	Dec. 31, 2019USD ($)	Jan. 02, 2019USD ($)	Sep. 13, 2017USD ($)
Rent payments		$ 960			$ 2,508
Lease term		8 years						2 years
Annual rent, year one								$ 39,200
Annual rent, year two								$ 42,000
Right of use assets			$ 385,436		385,436	$ 473,242	$ 529,135
Lease liabilities			$ 122,028		$ 122,028	$ 110,678	$ 531,462
Lease percentage			8.00%		8.00%
Lease present value			$ 559,568		$ 559,568
Lease expenses			72,428
Socialist Republic of Vietnam [Member]
Lease term	5 years
Annual rent, year one	$ 45,150
Annual rent, year two	$ 45,150
Area of Land | ft²	4,560.57
Socialist Republic of Vietnam [Member] | Three through Five Years [Member]
Rent increase percentage	5.00%
Related Party [Member]
Rent payments			9,819	$ 11,913
Lease expenses			$ 9,819

Right to Use Assets and Lease_4

Right to Use Assets and Lease Liability - Schedule of Right Use of Assets (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019	Jan. 02, 2019
Operating lease right-of-use asset, net	$ 385,436	$ 473,242	$ 529,135
Right to Use Assets Net - Related Party [Member]
Operating lease right-of-use asset, net	47,147
Right to Use Assets Net [Member]
Operating lease right-of-use asset, net	41,136
Right to Use Assets Net [Member]
Operating lease right-of-use asset, net	$ 297,153

Right to Use Assets and Lease_5

Right to Use Assets and Lease Liability - Schedule of Lease Liability (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019	Jan. 02, 2019
Total	$ 398,342
Less: short term portion	(122,028)	$ (110,678)	$ (531,462)
Long term position	276,314	$ 369,281
Right to Use Liability Net - Related Party [Member]
Total	49,466
Right to Use Liability Net [Member]
Total	42,918
Right to Use Liability Net [Member]
Total	$ 305,958

Right to Use Assets and Lease_6

Right to Use Assets and Lease Liability - Schedule of Lease Cost (Details)	9 Months Ended
	Sep. 30, 2020USD ($)
Operating Lease Expenses [Member]
Lease expenses	$ 33,866
Operating Lease Expenses [Member]
Lease expenses	34,743
Operating Lease Expenses - Related Party [Member]
Lease expenses	$ 9,819

Accrued Interest - Related Pa_2

Accrued Interest - Related Party (Details Narrative) - USD ($)	Sep. 10, 2020	Aug. 12, 2020	Jul. 16, 2020	Jun. 03, 2020	Apr. 08, 2020	Mar. 09, 2020	Feb. 19, 2020	Jan. 24, 2020	Dec. 18, 2019	Nov. 20, 2019	Mar. 01, 2019	Feb. 15, 2019	Feb. 01, 2019	Jan. 17, 2019	Jan. 04, 2019	Dec. 21, 2018	Oct. 12, 2018	Oct. 01, 2018	Jul. 05, 2018	Jun. 29, 2018	Jun. 21, 2018	Apr. 26, 2018	Mar. 31, 2018	Jan. 08, 2018	Dec. 01, 2017	Jun. 06, 2016	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Proceeds from debt	$ 100,000	$ 100,000	$ 100,000	$ 150,000	$ 100,000	$ 100,000	$ 100,000	$ 100,000	$ 100,000	$ 100,000	$ 20,000	$ 20,000	$ 30,000	$ 30,000	$ 3,000	$ 20,000	$ 11,000	$ 26,000	$ 20,000	$ 15,000	$ 15,000	$ 20,000	$ 15,000	$ 100,000	$ 30,000	$ 50,000
Debt Instrument, Interest rate																											3.00%		3.00%
Loans payable amount																											$ 1,492,000		$ 642,000
In-kind contribution of interest																											38,981	$ 16,027
Accrued interest																											$ 24,485	$ 10,624
Loan One [Member]
Proceeds from debt															$ 17,000

Note Payable (Details Narrative

Note Payable (Details Narrative) - USD ($)	Apr. 16, 2020	Mar. 01, 2019	Sep. 30, 2020	Sep. 30, 2019	Apr. 16, 2022	Dec. 31, 2019
Debt Instrument, Interest rate			3.00%			3.00%
Repayment of debt			$ 45,000	$ 8,000
First Six Months [Member]
Repayment of debt			1,000
Seven and Eight Months [Member]
Repayment of debt			2,000
Nine Through Twenty Three Months [Member]
Repayment of debt			5,000
24th Month [Member]
Notes payable			$ 180,224
Unsecured Promissory Note [Member] | Notre Dame [Member]
Notes payable		$ 265,244
Debt Instrument, Interest rate		10.00%
Debt instrument, term		24 months
Huntington National Bank [Member]
Loan	$ 90,100
Loan Interest Rate					1.00%

Stockholders' Deficit (Details

Stockholders' Deficit (Details Narrative) - USD ($)

Jul. 30, 2020

Feb. 19, 2020

Sep. 26, 2019

Aug. 14, 2019

Aug. 08, 2019

Apr. 05, 2019

Mar. 20, 2019

Mar. 09, 2019

Mar. 20, 2018

Feb. 16, 2009

Sep. 30, 2020

Sep. 30, 2019

Sep. 30, 2020

Sep. 30, 2019

Aug. 08, 2020

Dec. 31, 2019

Mar. 08, 2019

Dec. 17, 2013

Number of shares issued

766,667

7,967,871

4,052,652

Share price

$ 0.0695

Proceeds from issuance of common stock

$ 1,000,000

Warrants to purchase up share

1,000,000

8,000,000

Warrants exercise price

$ 0.001

$ 0.001

$ 0.001

$ 0.001

Stock issued during period, value

$ 281,659

$ 1,000,000

Issuance of common stock in connection with cashless exercise

9,941,623

10,000,000

9,000,000

10,000,000

9,000,000

Number of warrants cancelled

Preferred stock, no par value

Preferred stock, shares authorized

Unlimited

Unlimited

Unlimited

Contribution of capital

$ 17,495

Common Stock Class A [Member]

Common stock, no par value

Common stock, shares authorized

Unlimited

Unlimited

Unlimited

Common Stock Class B [Member]

Common stock, no par value

Common stock, shares authorized

Unlimited

Unlimited

Unlimited

Series A Preferred Stock [Member]

Preferred stock, no par value

Preferred stock, shares authorized

2

University of Notre Dame [Member]

Stock issued during period, value

38,500

Accounts payable

$ 243,159

Common Stock and Warrants [Member]

Number of shares issued

14,797,278

6 Cent Warrants [Member]

Warrants to purchase up share

14,797,278

Warrants exercise price

$ 0.06

8 Cent Warrants [Member]

Warrants to purchase up share

7,398,639

Warrants exercise price

$ 0.08

Warrant [Member]

Warrants exercise price

$ 0.06

0.001

0.001

0.001

Warrant expiration date

Mar. 8, 2021

Issuance of common stock in connection with cashless exercise

10,000,000

Warrant One [Member]

Warrants exercise price

$ 0.06

0.056

0.056

0.056

Warrant expiration date

Mar. 8, 2022

Warrant Two [Member]

Warrants exercise price

$ 0.08

0.04

0.04

0.04

Warrant expiration date

Mar. 8, 2022

Warrant Three [Member]

Warrants exercise price

$ 0.08

$ 0.06

$ 0.06

$ 0.06

Warrant expiration date

Mar. 8, 2023

Common Stock Warrants and Options [Member]

Number of shares issued

20,000,000

2,000,000

Share price

$ 0.115

$ 0.2299

Warrants to purchase up share

600,000

Warrants exercise price

$ 0.001

Option term

20 years

2 years

Fair value of options

$ 2,198,411

$ 267,574

Common stock warrants and options, description

Options will be exercisable on February 19, 2025, and for a period of 15 years expiring on February 19, 2040.

Options will be exercisable on August 8, 2020, and for a period of 3 years expiring on August 8, 2024.

Warrants will be exercisable on March 20, 2019, and for a period of 3 years expiring on March 20, 2022.

Share based compensation

$ 2,198,411

$ 267,574

Warrants term

4 years

Fair value of adjustments of warrants

$ 19,915

Warrants cancelled amount

$ 6,000

Number of warrants cancelled

600,000

Common Stock Warrants and Options One [Member]

Number of shares issued

6,000,000

Share price

$ 0.115

Option term

10 years

Fair value of options

$ 626,047

Common stock warrants and options, description

Black-Scholes option-pricing model on the date of grant and 2,000,000 options are fully vested on the date granted and 1,000,000 options vest at the end of each successive year for four years. Options will be exercisable on February 19, 2021, and for a period of 10 years expiring on February 19, 2030.

Share based compensation

272,673

Common Stock Warrants and Options Two [Member]

Number of shares issued

1,340,000

Share price

$ 0.115

Option term

7 years

Fair value of options

$ 133,063

Common stock warrants and options, description

Black-Scholes option-pricing model on the date of grant and 268,000 options are fully vested on the date granted and the remaining option vest equally over the remaining 4 years at the end of each successive year. Options will be exercisable on February 19, 2021, and for a period of 6 years expiring on February 19, 2027.

Share based compensation

40,935

Common Stock Warrants and Options One [Member]

Number of shares issued

2,000,000

Share price

$ 0.2299

Option term

2 years

Fair value of options

$ 267,574

Common stock warrants and options, description

Options will be exercisable on August 8, 2022, and for a period of 3 years expiring on August 8, 2025.

Share based compensation

161,568

Common Stock Warrants and Options Two [Member]

Number of shares issued

2,000,000

Share price

$ 0.2299

Option term

3 years

Fair value of options

$ 291,842

Common stock warrants and options, description

Options will be exercisable on August 8, 2023, and for a period of 3 years expiring on August 8, 2026.

Share based compensation

109,391

Common Stock Warrants and Options Three [Member]

Number of shares issued

1,000,000

Share price

$ 0.2299

Option term

2 years

Fair value of options

$ 118,874

Common stock warrants and options, description

Options will be exercisable on August 8, 2020, and for a period of 3 years expiring on August 8, 2023.

Share based compensation

118,874

Common Stock Warrants and Options Four [Member]

Number of shares issued

1,000,000

Share price

$ 0.2299

Option term

2 years

Fair value of options

$ 118,874

Common stock warrants and options, description

Options will be exercisable on August 8, 2021, and for a period of 3 years expiring on August 8, 2024.

Share based compensation

118,874

Common Stock Warrants and Options Five [Member]

Number of shares issued

125,000

Share price

$ 0.2299

Option term

2 years

Fair value of options

$ 14,859

Common stock warrants and options, description

Options will be exercisable on August 8, 2020, and for a period of 3 years expiring on August 8, 2023.

Share based compensation

14,859

Common Stock Warrants and Options Six [Member]

Number of shares issued

125,000

Share price

$ 0.2299

Option term

2 years

Fair value of options

$ 16,723

Common stock warrants and options, description

Options will be exercisable on August 8, 2022, and for a period of 3 years expiring on August 8, 2025.

Share based compensation

10,098

Common Stock Warrants and Options Seven [Member]

Number of shares issued

125,000

Share price

$ 0.2299

Option term

2 years

Fair value of options

$ 18,240

Common stock warrants and options, description

Options will be exercisable on August 8, 2023, and for a period of 3 years expiring on August 8, 2026.

Share based compensation

6,837

Common Stock Warrants and Options Eight [Member]

Number of shares issued

125,000

Share price

$ 0.2299

Option term

2 years

Fair value of options

$ 19,525

Common stock warrants and options, description

Options will be exercisable on August 8, 2024, and for a period of 3 years expiring on August 8, 2027.

Share based compensation

4,881

Common Stock Warrants and Options [Member]

Warrants expenses

$ 19,915

Chief Financial Officer [Member]

Contribution of capital

$ 17,495

Purchase Agreement [Member] | Investor [Member]

Number of shares issued

14,797,278

Share price

$ 0.06758

Proceeds from issuance of common stock

$ 1,000,000

Stockholders' Deficit - Schedul

Stockholders' Deficit - Schedule of Option Assumption (Details)	Feb. 19, 2020	Aug. 08, 2019	Mar. 20, 2018
Common Stock Warrants and Options [Member]
Expected dividends	0.00%
Expected volatility	125.19%
Expected term	3 years
Risk free interest rate	1.56%
Expected forfeitures	0.00%
Common Stock Warrants and Options One [Member]
Expected dividends	0.00%
Expected volatility	125.19%
Expected term	3 years
Risk free interest rate	1.50%
Expected forfeitures	0.00%
Common Stock Warrants and Options Two [Member]
Expected dividends	0.00%
Expected volatility	125.19%
Expected term	6 years
Risk free interest rate	1.46%
Expected forfeitures	0.00%
Common Stock Warrants and Options [Member]
Expected dividends		0.00%
Expected volatility		105.73%
Expected term		2 years
Risk free interest rate		1.62%
Expected forfeitures		0.00%
Common Stock Warrants and Options One [Member]
Expected dividends		0.00%
Expected volatility		105.73%
Expected term		2 years
Risk free interest rate		1.62%
Expected forfeitures		0.00%
Common Stock Warrants and Options Two [Member]
Expected dividends		0.00%
Expected volatility		105.73%
Expected term		3 years
Risk free interest rate		1.54%
Expected forfeitures		0.00%
Common Stock Warrants and Options Three [Member]
Expected dividends		0.00%
Expected volatility		105.73%
Expected term		2 years
Risk free interest rate		1.62%
Expected forfeitures		0.00%
Common Stock Warrants and Options Four [Member]
Expected dividends		0.00%
Expected volatility		105.73%
Expected term		2 years
Risk free interest rate		1.62%
Expected forfeitures		0.00%
Common Stock Warrants and Options Five [Member]
Expected dividends		0.00%
Expected volatility		105.73%
Expected term		2 years
Risk free interest rate		1.62%
Expected forfeitures		0.00%
Common Stock Warrants and Options Six [Member]
Expected dividends		0.00%
Expected volatility		105.73%
Expected term		2 years
Risk free interest rate		1.62%
Expected forfeitures		0.00%
Common Stock Warrants and Options Seven [Member]
Expected dividends		0.00%
Expected volatility		105.73%
Expected term		3 years
Risk free interest rate		1.54%
Expected forfeitures		0.00%
Common Stock Warrants and Options Eight [Member]
Expected dividends		0.00%
Expected volatility		105.73%
Expected term		3 years
Risk free interest rate		1.54%
Expected forfeitures		0.00%
Common Stock Warrants and Options Nine [Member]
Expected dividends			0.00%
Expected volatility			97.56%
Expected term			4 years
Risk free interest rate			2.65%
Expected forfeitures			0.00%

Stockholders' Deficit - Sched_2

Stockholders' Deficit - Schedule of Warrants Activity (Details)	9 Months Ended
	Sep. 30, 2020USD ($)$ / sharesshares
Equity [Abstract]
Number of Warrants, Beginning balance | shares	55,395,917
Number of Warrants, Granted | shares
Number of Warrants, Exercised | shares	(10,000,000)
Number of Warrants, Cancelled/Forfeited | shares
Number of Warrants, Ending balance | shares	45,395,917
Number of Warrants, Intrinsic Value | $	$ 9,799,286
Weighted Average Exercise Price, Beginning balance
Weighted Average Exercise Price, Granted
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Cancelled/Forfeited
Weighted Average Exercise Price, Ending balance
Weighted Average Exercise Price, Intrinsic Value
Weighted Average Remaining Contractual Life (In Years), Beginning balance	2 years 9 months 7 days
Weighted Average Remaining Contractual Life (In Years), Ending balance	2 years 7 days

Stockholders' Deficit - Sched_3

Stockholders' Deficit - Schedule of Warrants Outstanding (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019	Sep. 30, 2019	Mar. 09, 2019
Exercise Price Warrants Outstanding	$ 0.001		$ 0.001
Weighted Average Remaining Contractual Life	2 years 9 months 7 days
Aggregate Intrinsic Value	$ 9,799,286
Warrant [Member]
Exercise Price Warrants Outstanding	$ 0.001	$ 0.001		$ 0.06
Warrants Exercisable	11,000,000	21,000,000
Weighted Average Remaining Contractual Life	9 months 18 days	1 year 7 months 24 days
Aggregate Intrinsic Value	$ 4,326,000	$ 4,069,800
Warrant One [Member]
Exercise Price Warrants Outstanding	$ 0.056	$ 0.056		0.06
Warrants Exercisable	3,000,000	3,000,000
Weighted Average Remaining Contractual Life	10 months 10 days	1 year 7 months 10 days
Aggregate Intrinsic Value	$ 618,000	$ 387,600
Warrant Two [Member]
Exercise Price Warrants Outstanding	$ 0.04	$ 0.04		0.08
Warrants Exercisable	2,300,000	2,300,000
Weighted Average Remaining Contractual Life	10 months 25 days	1 year 8 months 12 days
Aggregate Intrinsic Value	$ 473,800	$ 445,740
Warrant Three [Member]
Exercise Price Warrants Outstanding	$ 0.06	$ 0.06		$ 0.08
Warrants Exercisable	7,398,639	7,398,639
Weighted Average Remaining Contractual Life	5 months 9 days	1 year 2 months 8 days
Aggregate Intrinsic Value	$ 1,524,120	$ 1,433,856
Warrant Four [Member]
Exercise Price Warrants Outstanding	$ 0.06	$ 0.06
Warrants Exercisable	7,398,639	7,398,639
Weighted Average Remaining Contractual Life	1 year 5 months 9 days	2 years 2 months 8 days
Aggregate Intrinsic Value	$ 1,524,120	$ 1,433,856
Warrant Five [Member]
Exercise Price Warrants Outstanding	$ 0.08	$ 0.08
Warrants Exercisable	3,699,320	3,699,320
Weighted Average Remaining Contractual Life	1 year 5 months 9 days	2 years 2 months 8 days
Aggregate Intrinsic Value	$ 762,060	$ 716,928
Warrant Six [Member]
Exercise Price Warrants Outstanding	$ 0.08	$ 0.08
Warrants Exercisable	3,699,320	3,699,320
Weighted Average Remaining Contractual Life	2 years 5 months 9 days	3 years 2 months 8 days
Aggregate Intrinsic Value	$ 762,060	$ 719,928
Warrant Seven [Member]
Exercise Price Warrants Outstanding	$ 0.2299	$ 0.2299
Warrants Exercisable	8,500,000	8,500,000
Weighted Average Remaining Contractual Life	4 years 7 months 17 days	5 years 4 months 20 days
Aggregate Intrinsic Value	$ 1,751,000	$ 1,647,300

Stockholders' Deficit - Sched_4

Stockholders' Deficit - Schedule of Options Outstanding (Details)	9 Months Ended
	Sep. 30, 2020$ / sharesshares
Equity [Abstract]
Exercise Price | $ / shares	$ 0.115
Options Outstanding
Options Exercisable	22,267,800
Weighted Average Remaining Contractual Life	22 years 9 months 18 days

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative)	Oct. 21, 2019USD ($)	Sep. 26, 2019shares	Sep. 05, 2019USD ($)	Aug. 15, 2019USD ($)	Aug. 14, 2019shares	Jul. 03, 2019USD ($)$ / sharesshares	May 09, 2019USD ($)ft²	Apr. 26, 2019USD ($)	Apr. 05, 2019shares	Mar. 20, 2019USD ($)shares	Jan. 31, 2019USD ($)shares	Apr. 06, 2018USD ($)$ / sharesshares	Mar. 20, 2018USD ($)$ / sharesshares	Feb. 20, 2018USD ($)shares	Jan. 09, 2018	Sep. 13, 2017USD ($)	Jan. 23, 2017USD ($)	Jan. 14, 2016USD ($)$ / sharesshares	Jan. 20, 2015USD ($)$ / sharesshares	Oct. 28, 2011shares	Nov. 10, 2010USD ($)	May 01, 2008USD ($)$ / shares	Dec. 26, 2006USD ($)	May 08, 2006USD ($)	Jan. 31, 2007USD ($)	Sep. 30, 2020USD ($)$ / shares	Sep. 30, 2019USD ($)$ / shares	Sep. 30, 2020USD ($)$ / shares	Sep. 30, 2019USD ($)$ / shares	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Sep. 30, 2020USD ($)$ / shares	Dec. 31, 2019USD ($)	Oct. 28, 2015shares	May 28, 2015$ / sharesshares
Annual salary																										$ 161,861	$ 129,577	$ 361,276	$ 395,782
Warrant exercise price | $ / shares																										$ 0.001	$ 0.001	$ 0.001	$ 0.001							$ 0.001
Working capital																										$ 6,908,522		$ 6,908,522								$ 6,908,522
Number of shares issued | shares		766,667			7,967,871					4,052,652
Payment for debt																												45,000	$ 8,000
Stock issued during period, value										$ 281,659																			1,000,000
Consulting fee																										39,169	$ 54,230	89,643	242,458
Interest expense and related accrued interest payable																										24,485	$ 10,624	24,485	10,624							24,485
Payments for rent																	$ 960																			2,508
Annual rent, year one																$ 39,200
Annual rent, year two																42,000
Socialist Republic of Vietnam [Member]
Annual rent, year one							$ 45,150
Annual rent, year two							$ 45,150
Area of Land | ft²							4,560.57
Three through Five Years [Member] | Socialist Republic of Vietnam [Member]
Rent increase percentage							5.00%
Mr. Jonathan R. Rice [Member]
Payroll payable																										95,467		95,467			$ 64,351					95,467	$ 64,351
Employment Agreement [Member]
Extended expiration date description															The Company extended the expiration date of a warrant for 2,000,000 shares of common stock from January 19, 2018 to January 31, 2020 and on January 10, 2020, the Company extended the expiration date of the warrant to January 23, 2015 for Mr. Rice.
Employment Agreement [Member] | CEO [Member]
Agreement term																					5 years										5 years		5 years	5 years
Annual salary																					$ 210,000										$ 334,708		$ 315,764	$ 297,889	$ 281,027
Annual salary rate, increase																					6.00%
Accrued salary balance																										2,710,706		2,710,706			2,535,203					2,710,706	2,535,203
Employment Agreement [Member] | CEO [Member] | Forecast [Member]
Agreement term																														5 years
Annual salary																														$ 376,078
Employment Agreement [Member] | Employee [Member]
Employee bonus rate																																			20.00%
Employment Agreement [Member] | Mr. Jonathan R. Rice [Member]
Agreement term																		1 year	1 year
Annual salary	$ 20,000			$ 20,000				$ 20,000
Annual cash compensation																		$ 140,000	$ 120,000
Educational expenses																			$ 11,000
Warrant term																		3 years
Warrant to purchase shares | shares																		6,000,000
Warrant exercise price | $ / shares																		$ 0.001
Warrant shares fully vested | shares																																						2,000,000
Warrants issued value																																			$ 121,448
Extended expiration date description															The Company extended the expiration date of the January 2015 warrant from January 19, 2018 to January 31, 2020, and on January 10, 2020 the Company extended the expiration date of the warrant to January 23, 2015 and on March 15, 2018, the Company signed an extension of its at-will employment agreement with its COO, extending the term to January 31, 2019.
Working capital	$ 6,000,000			$ 6,000,000
Ownership percentage	50.00%			50.00%
Employment Agreement [Member] | Mr. Jonathan R. Rice [Member] | January 2015 Warrant [Member]
Warrant term																			3 years
Warrant to purchase shares | shares																			2,000,000
Warrant exercise price | $ / shares																			$ 0.001
Employment Agreement [Member] | Mr. Jonathan R. Rice [Member] | May 2015 Warrant [Member]
Warrant term																																							3 years
Warrant to purchase shares | shares																																							3,000,000
Warrant exercise price | $ / shares																																							$ 0.001
Employment Agreement [Member] | Mr. Jonathan R. Rice [Member] | One-Time Bonus [Member]
Annual salary								$ 20,000
Employment Agreement [Member] | Mr. Kenneth Le [Member]
Agreement term						1 year
Accrued salary balance																										1,961		1,961			1,154					1,961	1,154
Annual cash compensation						$ 60,000
Warrant term						3 years
Warrant to purchase shares | shares						2,000,000
Warrant exercise price | $ / shares						$ 0.2299
License Agreement [Member]
Agreement term																				20 years				1 year
License fee																								$ 10,000
License maintenance fee																								$ 10,000
Annual research fee																									$ 13,700
Number of shares issued | shares																				2,200,000
Royalty percentage																				2.00%
Termination agreement description																				The Company can terminate the agreement upon a 90 day written notice subject to payment of a termination fee of $5,000 if the termination takes place within 2 years after its effectiveness, $10,000 if the termination takes place within 4 years after its effectiveness and $20,000 if the Agreement is terminated after 4 years
Payment for debt																												45,000
License Agreement [Member] | Maximum [Member]
Annual research fee																									$ 10,000
License Agreement [Member] | Common Stock Class A [Member]
Number of shares issued | shares											4,025,652
Payment for debt											$ 265,244
Stock issued during period, value											$ 281,659
Royalty and Research Agreements [Member]
Agreement term																						5 years
Consulting fee																						$ 1,000
Interest expense and related accrued interest payable																										8,013		8,013			2,623					8,013	2,623
Royalty and Research Agreements [Member] | Maximum [Member]
Shares issued, price per share | $ / shares																						$ 0.05
Royalty and Research Agreements [Member] | Forecast [Member]
Interest expense and related accrued interest payable																														$ 1,469
Royalty and Research Agreements [Member] | Consultant [Member]
Number of shares issued | shares												36,000
Stock issued during period, value												$ 1,076
Consulting fee																																					21,000
Shares issued, price per share | $ / shares												$ 0.0299
Gain on settlement of accounts payable																																					19,924
Royalty and Research Agreements [Member] | Mr. Thompson [Member]
Payment for debt																							$ 120,000
Maturity date																							Dec. 26, 2007
Outstanding balance																										$ 65,292		65,292			$ 65,292					$ 65,292	$ 65,292
Consulting Agreement [Member] | Consultant [Member]
Annual cash compensation														$ 6,000
Warrant term													4 years
Warrant to purchase shares | shares													600,000	600,000
Warrant exercise price | $ / shares													$ 0.001
Fair value of warrants													$ 19,915
Warrants exercisable date													Mar. 20, 2019
Warrants exercisable description													Warrants will be exercisable on March 20, 2019, and for a period of 3 years expiring on March 20, 2022.
Warrants expenses																																$ 19,915
Cancelled warrant issued | shares									600,000
Consulting Agreement [Member] | Consultant [Member] | Maximum [Member]
Warrant to purchase shares | shares														3,000,000
Operating Lease Agreements [Member]
Payments for rent			$ 44,800													$ 39,200												2,508
Operating lease, term			2 years													2 years
Operating lease, description			The Company signed a new two-year lease for this 5,000 square foot property in Lansing, MI that commenced on October 1, 2019 and ends on September 30, 2021, for its research and development headquarters.
Operating leases, rent expense																												9,819	$ 11,913
Operating Lease Agreements [Member] | Office and Manufacturing Space [Member]
Payments for rent																$ 42,000
Operating Lease Agreements [Member] | Socialist Republic of Vietnam [Member]
Operating lease, term							5 years
Operating lease, description							The Company signed a 5 year property lease Socialist Republic of Vietnam which consists of 4,560.57 square meters of space, which it leases at a current rent of approximately $45,150 per year one and two and with the 5% increase per year for years three through five.
Annual rent, year one							$ 45,150
Annual rent, year two							$ 45,150
Area of Land | ft²							4,560.57
Operating Lease Agreements [Member] | Three through Five Years [Member] | Socialist Republic of Vietnam [Member]
Rent increase percentage							5.00%
Operating Lease Agreements [Member] | President [Member]
Payments for rent																	$ 960											$ 960
Operating lease, term																	8 years

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	Sep. 10, 2020	Aug. 12, 2020	Jul. 16, 2020	Jun. 03, 2020	Apr. 08, 2020	Feb. 19, 2020	Jan. 24, 2020	Dec. 18, 2019	Nov. 20, 2019	Oct. 21, 2019	Sep. 26, 2019	Sep. 05, 2019	Aug. 15, 2019	Aug. 14, 2019	Jul. 03, 2019	Apr. 26, 2019	Mar. 20, 2019	Mar. 02, 2019	Feb. 15, 2019	Feb. 01, 2019	Jan. 17, 2019	Jan. 05, 2019	Jan. 04, 2019	Dec. 21, 2018	Oct. 12, 2018	Oct. 02, 2018	Jul. 05, 2018	Jun. 29, 2018	Jun. 21, 2018	Apr. 26, 2018	Mar. 31, 2018	Jan. 09, 2018	Jan. 08, 2018	Sep. 13, 2017	Jan. 23, 2017	Jun. 06, 2016	Jan. 14, 2016	Jan. 20, 2015	Nov. 10, 2010	Dec. 26, 2006	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Aug. 14, 2020	Sep. 30, 2020
Number of shares issued											766,667			7,967,871			4,052,652
Stock issued during period, value																	$ 281,659																											$ 1,000,000
Accrued interest percentage																																									3.00%		3.00%		3.00%					3.00%
Interest expense and related accrued interest payable																																									$ 24,485	$ 10,624	$ 24,485	10,624						$ 24,485
Annual salary																																									$ 161,861	$ 129,577	$ 361,276	$ 395,782
Warrant exercise price																																									$ 0.001	$ 0.001	$ 0.001	$ 0.001						$ 0.001
Working capital																																									$ 6,908,522		$ 6,908,522							$ 6,908,522
In-kind contribution of interest																																											38,981	$ 16,027
Payments for rent																																			$ 960															2,508
Related Party [Member]
Interest expense and related accrued interest payable																																									1,411,414		1,411,414		$ 1,196,503					1,411,414
Loan interest - related party																																									69,669		69,669		43,715					69,669
Royalty payable to related party																																											65,292		65,292
Mr. Jonathan R. Rice [Member]
Payroll payable																																									$ 95,467		$ 95,467		64,351					$ 95,467
Stockholder [Member]
Accrued interest percentage																																									3.00%		3.00%							3.00%
Interest expense and related accrued interest payable																																									$ 24,485	$ 10,624	$ 24,485	10,624						$ 24,485
Loan received	$ 100,000	$ 100,000	$ 100,000	$ 150,000	$ 100,000	$ 100,000	$ 100,000	$ 100,000	$ 100,000									$ 20,000	$ 20,000	$ 30,000	$ 30,000	$ 17,000	$ 3,000	$ 20,000	$ 11,000	$ 26,000	$ 20,000	$ 15,000	$ 15,000	$ 20,000	$ 15,000		$ 100,000			$ 50,000													$ 30,000
Loans payable																																									1,492,000		1,492,000		642,000					1,492,000
In-kind contribution of interest																																											38,981	16,027
Chief Executive Officer and Chief Operations Officer [Member]
Accounts payable and accrued expenses																																									325,516		325,516		304,539					325,516
Principal Stockholder [Member]
Accrued salary balance																																									2,710,706		2,710,706		2,535,203					2,710,706
Chief Operating Officer [Member]
Accrued salary balance																																									95,467		95,467		64,351					95,467
Board of Directors [Member]
Accrued salary balance																																									1,962		1,962		1,153					1,962
Office Employee [Member]
Accrued salary balance																																									22,900		22,900		$ 4,477					22,900
Intellectual Property Transfer Agreement [Member] | Mr. Thompson [Member]
Number of shares issued																																								200,000
Dividends, preferred stock
Preferred stock voting rights																																								Voting rights equal to 100 common shares per share of preferred stock
Stock issued during period, value																																								$ 120,000
Fair value of the payment																																								$ 120,000
Maturity date																																								Dec. 26, 2007
Debt instrument, term																																								1 year
Outstanding balance																																									$ 65,292		$ 65,292							$ 65,292
Accrued interest percentage																																									7.00%		7.00%							7.00%
Interest expense and related accrued interest payable																																									$ 8,013		$ 8,013							$ 8,013
Employment Agreement [Member]
Extended expiration date description																																The Company extended the expiration date of a warrant for 2,000,000 shares of common stock from January 19, 2018 to January 31, 2020 and on January 10, 2020, the Company extended the expiration date of the warrant to January 23, 2015 for Mr. Rice.
Employment Agreement [Member] | CEO [Member]
Agreement term																																							5 years						5 years	5 years	5 years
Annual salary																																							$ 210,000						$ 334,708	$ 315,764	$ 297,889	$ 281,027
Accrued salary balance																																									2,710,706		2,710,706		2,535,203					2,710,706
Employment Agreement [Member] | Mr. Jonathan R. Rice [Member]
Agreement term																																					1 year	1 year
Annual salary										$ 20,000			$ 20,000			$ 20,000
Annual cash compensation																																					$ 140,000	$ 120,000
Warrant term																																					3 years
Warrant to purchase shares																																					6,000,000
Warrant exercise price																																					$ 0.001
Extended expiration date description																																The Company extended the expiration date of the January 2015 warrant from January 19, 2018 to January 31, 2020, and on January 10, 2020 the Company extended the expiration date of the warrant to January 23, 2015 and on March 15, 2018, the Company signed an extension of its at-will employment agreement with its COO, extending the term to January 31, 2019.
Working capital										$ 6,000,000			$ 6,000,000
Ownership percentage										50.00%			50.00%
Employment Agreement [Member] | Mr. Jonathan R. Rice [Member] | One-Time Bonus [Member]
Annual salary																$ 20,000
Employment Agreement [Member] | Mr. Kenneth Le [Member]
Agreement term															1 year
Accrued salary balance																																									$ 1,961		1,961		$ 1,154					$ 1,961
Annual cash compensation															$ 60,000
Warrant term															3 years
Warrant to purchase shares															2,000,000
Warrant exercise price															$ 0.2299
Operating Lease Agreements [Member]
Operating lease, term												2 years																						2 years
Payments for rent												$ 44,800																						$ 39,200									2,508
Operating Lease Agreements [Member] | President [Member]
Operating lease, term																																			8 years
Payments for rent																																			$ 960								960
Operating leases, rent expense																																											$ 9,819	$ 11,913

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Nov. 04, 2020	Sep. 30, 2020	Dec. 31, 2019
Interest on loan		3.00%	3.00%
Subsequent Event [Member]
Loan received	$ 30,000
Interest on loan	3.00%